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Influenza A virus encodes M2, a proton channel that has been shown to be
important during virus entry and assembly. The primary aim of this thesis was to
investigate the role of the membrane proximal region, residues 46-69, of the M2
cytoplasmic tail during virus replication. A cholesterol recognition/interaction amino
consensus (CRAC) motif, previously identified in the membrane proximal region of
M2 in some influenza A virus strains, was suggested to play a role in virus
replication by mediating incorporation of M2 into budding virus particles. Alteration
or completion of the M2 CRAC motif in two different recombinant virus strains
caused no changes in virus replication in tissue culture; however, viruses lacking an
M2 CRAC motif had decreased morbidity and mortality in the mouse model of
infection. In order to further investigate the role of the membrane proximal residues
of M2 in basic virus replication, scanning and directed alanine mutants were
generated and analyzed in trans-complementation assays and recombinant viruses.
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The membrane proximal residues 46-69 tolerated numerous mutations with little, if
any, affect on virus replication suggesting that the identity of individual amino acids
in this region are less important than the overall protein structure for the M2 protein
function. The requirement during virus replication of the ectodomain and the
cytoplasmic tail of M2, which includes the membrane proximal region, was further
characterized using the influenza C virus CM2 protein and a chimeric influenza A
virus M2 protein (MCM) containing the CM2 transmembrane domain. While M2,
CM2, and MCM could all alter cytosolic pH to varying degrees when expressed
from cDNA, only M2 and MCM could at least partially complement an M2-null
virus in a trans-complementation system. This data suggests that while the CM2 ion
channel activity is similar to that of M2, sequences in the ectodomain and/or
cytoplasmic tail play important roles in infectious virus production. This thesis
suggests that the structure of the membrane proximal region of the M2 cytoplasmic
tail may stabilize the membrane distal region, which mediates genome incorporation.
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CHAPTER 1

Introduction

Shaun M. Stewart
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Influenza Virus Pathogenesis
Influenza A virus is a member of the Orthomyxovirdae family whose genome
consists of 8 negative-sense RNA segments which encode 10 or 11 proteins. Influenza A
virus remains a major public health burden even with widespread annual vaccination and
the availability of antivirals. Each year more than 230,000 hospitalizations and 50,000
deaths in the United States alone are associated with influenza related illness (148, 149).
Two types of vaccines are currently on the market, a trivalent inactivated vaccine (TIV)
and a trivalent live attenuated influenza vaccine (LAIV) [reviewed in (29)]. However,
annual vaccination is indicated for both vaccines because neither generates long term
immunity to the ever evolving influenza viruses. Influenza viruses undergo two forms of
genetic variation. The immune response of infected individuals, primarily against the
viral glycoproteins hemagglutinin (HA) and neuraminidase (NA), provides selective
pressure that allows naturally occurring variants with replication advantages, which arise
through random mutagenesis, to escape preexisting population immunity, termed genetic
drift. A more drastic change in circulating strains can occur when two strains co-infect a
single cell and give arise to recombinants that have a mix of the viral RNA from the two
viruses, termed genetic shift. Genetic drift is one reason why we require annual
vaccination while genetic shift can give rise to potential pandemic strains for which few
in the population have immunity against, such as happened in 1918 and 2009 (100).
Antivirals also exist that help decrease the severity and duration of disease but they must
be administered very early during infection in order to be efficacious and resistance
easily arises against these drugs [reviewed in (48)]. The two classes of antiviral
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medications are the neuraminidase inhibitors, Oseltamivir and Zanamivir, and M2
inhibitors, Rimantadine and Amantadine.
Due to the threat of future pandemics, the unpredictability of which influenza
strains will circulate in a given year, and the existence of resistance to all current
influenza antivirals, continued research on the basic viriology of influenza A virus is
warranted.

Assembly of Infectious Virus and Virus-Like Particles
There are at least four different types of enveloped viral products that can be
assembled and released from the plasma membrane of host cells, virus-like particles
(VLPs), pseudotyped VLPs, pseudotyped virus particles, and infectious virus particles.
Enveloped VLPs are characterized by a cell membrane derived envelope that
incorporates at least one viral glycoprotein or internal structural protein (Fig 1A). If any
viral genetic material is present, it is either incomplete or artificial; therefore, VLPs are
non-replicating. Pseudotyped VLPs are generated by the co-expression of glycoproteins
from one or more viruses along with the internal core proteins from a different host virus
(Fig 1B). Like VLPs, the genetic material in pseudotyped VLPs is either incomplete or
artificial, if present at all, and the particles are non-replicating. Pseudotyped virus
particles are generated by the co-expression of glycoproteins from one or more viruses in
cells infected by another virus that either has a complete complement of genes or does
not encode its own glycoproteins (Fig 1C). The potential infectivity of pseudotyped virus
particles depends on whether the host virus used to infect the cells is fully replication
competent. Often host viruses are utilized that contain genetic deletions in order to
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produce particles that cannot replicate. If pseudotyped virus particles are non-replicating,
they might also be termed pseudotyped VLPs. However, for the purpose of this thesis,
when the foreign glycoprotein is expressed in trans and not from the viral genome of the
parent VLP, the particles can never replicate and we term them pseudotyped VLPs.
Whereas pseudotyped particles formed when the host viral genome is engineered to
express a foreign glycoprotein will be termed pseudotyped virus particles even if they are
unable to replicate. Infectious virus particles, unlike VLPs and pseudotyped VLPs,
contain a complete viral genome and complement of structural proteins, all from the same
virus (Fig 1D). The differences between these four distinct viral particles will be
illustrated using vesicular stomatitis virus (VSV), human immunodeficiency virus (HIV),
and finally influenza A virus.

Virus-Like Particles
The expression of viral glycoproteins or internal proteins is often sufficient to
induce the release of enveloped particles from the surface of cells. Despite lacking a
complete viral genome and, sometimes, the internal structural proteins, VLPs often retain
similar morphology to infectious virus particles. However, the lack of expression of one
or more internal proteins can alter packaging organization and result in particles with
larger diameters or more pleiotropic morphology than those of infectious virus particles
(123). Due to their lack of a complete viral genome, VLPs are non-replicating. They can
be generated by transient expression of one or more of the structural proteins. Several
techniques used for expression include transfection of mammalian expression vectors,
infection with a recombinant vaccinia virus encoding a T7 bacteriophage polymerase
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(vvT7) and transfection with a T7 polymerase-driven expression vector, transfection with
an alphavirus replicon which encodes one or more structural proteins from another virus,
or infection with an unrelated virus, such an alphavirus or a baculovirus, which has been
engineered to express one or more structural proteins from another virus. VLPs are used
to study the role of various viral proteins in virus attachment, fusion, and assembly. They
have also been safely used as vaccines in animals and humans.
Vesicular Stomatitis Virus (VSV) VLPs
One VSV VLP system is characterized by the expression of the vesicular
stomatitis virus G glycoprotein (VSV-G) from a Semliki Forest virus (SFV) replicon
(123). In this system, VSV-G is sufficient to induce VLP formation and the SFV replicon
gets incorporated into the VLPs randomly. However, the envelopes of VLPs are derived
from the host, and host proteins may be involved in the release of VLPs. Therefore, the
choice of host can greatly affect the production and composition of these particles. VSVG VLPs are cell system dependent because the system produces VLPs well in BHK,
CHO, and C6/36 cells, less well in NRK and COS cells, and not at all in HeLa cells
(123). This system, although able to replicate, is considered a VLP here because only the
viral glycoprotein is expressed. However, it could, more accurately, be considered a
simple manmade virus. A modification of this system, to generate replication
incompetent VSV VLPs, expresses the VSV-G from a plasmid that is co-transfected
along with the SFV replicon which expresses another gene of interest (24). The latter
system avoids the overproduction of the cytotoxic VSV-G protein in cells infected with
the VSV VLPs and could enable use of this technology as a transduction vector.
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The matrix protein from VSV (VSV-M) has also been shown to be sufficient
when expressed alone to induce VLP formation in Sf9 insect cells using a baculovirus
expression system (82) and in CV1 cells using a vvT7 infection/transfection system (64).
HIV VLPs
The core structure of HIV is encoded by the gag gene which is translated as a
precursor polyprotein, Pr55gag (MA-CA-NC-p6), which is processed during or after virus
particle budding by the protease (PR) protein encoded by the viral pol gene to form, from
N-terminus to C-terminus, the major core proteins matrix (MA), capsid (CA),
nucleocapsid (NC), and p6. Expression of uncleaved Pr55gag alone using a baculovirus
expression system is sufficient to form VLPs in Sf9 cells (38). Pr55gag is myristylated at
the N-terminal glycine residue in MA and induces budding from a type of membrane
microdomain enriched in cholesterol, glycosphingolipids, and sphingomyelin [(108),
reviewed in (152)], often called lipid rafts [reviewed in (136)]. Pr55gag has two modes of
membrane binding [reviewed in (20)]. If the myristylation site is mutated (38) or
myristylation is chemically inhibited (97), Pr55gag fails to bind membranes and induce
VLP release, but instead forms circular structures in the cytoplasm and/or nucleus.
However, a basic patch on MA of Pr55gag is also important for membrane binding and
directs interactions with acidic phospholipids, particularly phosphatidylinositol 3,4bisphosphate [PI(3,4)P2] (19, 107, 141, 164). Unlike membrane binding, p6 is not
required for virus-like particle formation and release (52, 127). However, expression of a
MA-CA construct without NC and p6 results in long tubular structures attached to cells
(38, 52) or a vastly decreased number of spherical particles attached to cells (127). CANC and CA-NC-p6 can form protein cylinders (13) and MA-CA-NC and MA-CA-NC-p6
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(Pr55gag) can form spheres (12) in vitro in the presence of nucleic acid and in the absence
of myristylation and phospholipids. This suggests that nucleic acid is important for HIV
VLP formation and that it can occur with only expression of Pr55gag. Addtionally, Env
expression does not increase release of particles (38).
Strategies utilizing HIV VLPs in attempts to generate an HIV vaccine are too
numerous to exhaustively describe here [reviewed in (161)]. However, one interesting
example that has undergone human clinical trials in various forms includes the expression
of Gag, Env, and PR from a canarypox vaccine (28, 91). Infection of mammalian cells
with canarypox virsues is abortive and results in only one round of infection. During this
one round of infection, expression of the HIV proteins leads to the release of VLPs which
are able to generate CTL responses in some individuals [reviewed in (91)].
Influenza Virus VLPs
Like VSV, formation of influenza virus VLPs are affected by the host and
expression system utilized. For instance, Cos-1, CV-1, and HeLa cells expressing
influenza matrix protein (M1) via a vvT7 infection/transfection system (17, 40) and Sf9
cells expressing M1 using a baculovirus expression system produce VLPs (68, 77, 117,
140) (Fig 2A) while BHK cells expressing M1 via a semliki forest virus (an alphavirus)
replicon do not result in VLP production (163). In the latter example, 3 hours post
transfection was the latest time point investigated, and it is possible that VLPs might have
been detected at later time points. Others have shown that in 293T cells, expression of
either M1 or the proton channel matrix 2 protein (M2) alone by mammalian expression
vectors results in the production of VLPs (Fig 2A and B), but co-expression of the
glycoprotein neuraminidase (NA) or both the glycoproteins hemagglutinin (HA) and NA
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together increases the number of VLPs produced (17, 76). Additionally, the level of M1,
but not HA or NA, expression, has also been shown to be correlated with the level of
VLP production when measured by the incorporation of a reporter gene (102).
Correlation of M1 and reporter gene levels may relate to the role of M1 during genome
packaging.
It has been reported that expression of HA alone is insufficient to produce VLPs
(77). However, these experiments do not take into account that, during both viral entry
and egress, HA binds sialic acid and will result in retention or clumping of budded VLPs
and virus particles unless sialidase activity is present either in a co-expressed NA or in
exogenously added NA (17, 41, 83, 110). In fact, several reports have now shown that
expression of HA alone can produce VLPs when an NA is added exogenously (17, 76)
(Fig 2C). Additionally, both insect and plant cells, which usually do not produce proteins
containing terminal sialic acid resides (90, 134), can also be used to produce HA
containing VLPs in the absence of NA (23, 32, 33, 45, 72, 117, 119).
Recently, several groups have investigated the ability of NA to induce VLPs in
the absence of the other viral proteins. Expression of some strains of NA alone are able to
induce VLP formation while others are not (76, 77, 160) (Fig 2D).
All of these studies taken together show that in various systems, the expression of
M1, M2, HA, or NA alone is sufficient to produce influenza A virus VLPs (Fig 2).
Differences in the expression systems and cellular hosts may account for why each
system shows that a different protein is necessary and sufficient for VLP formation.
Assembly and release of VLPs is highly dependent on cellular processes like expression
levels and locations, glycosylation, vesicular sorting, and trafficking. Each cell system
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may have slight differences in these or other cellular processes which are required for,
contribute to, or restrict the production of VLPs.
Influenza virus VLPs have been used to successfully induce protective
immunological responses in animals [reviewed in (67)] when expressing M1 and M2 (Fig
2E) (139, 140), HA and M1 (Fig 2F) (32, 33, 68, 72, 117, 119, 138), M1, HA, and NA
(Fig 2G) (3, 4, 88, 115, 116, 144), M1, HA, NA, and M2 (Fig 2H) (93, 158), and all viral
proteins minus NS2/NEP (154), but not M1 alone (140). Influenza virus VLPs expressing
HA, NA, and M1 are currently moving through human clinical trials (70). Influenza virus
VLPs and inactivated vaccines can both be multivalent (29, 114, 119). VLPs have also
been considered as a supplement to inactivated vaccines in an attempt to broaden the
cross protection (139) and have been utilized as a carrier to present foreign glycoproteins
which will be discussed below as pseudotyped VLPs.

Pseudotyped Virus-Like Particles
Pseudotyped VLPs are produced like VLPs except that one or more glycoproteins
are co-expressed from a different virus. There are two advantages to generating
pseudotyped VLPs. One is if the glycoprotein of interest does not induce VLP formation,
then core proteins from a virus known to induce VLPs can be used to generate
pseudotyped VLPs that incorporate the glycoprotein of interest. A second purpose is that
VLPs from a characterized system can used to quickly generate new ones that express a
glycoprotein from another virus without the development of new characterization or
purification protocols. The simultaneous expression of glycoproteins from one or more
viruses along with the internal proteins from another virus has been achieved via several
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mechanisms. The glycoproteins from one virus can be co-expressed with the internal
proteins from another virus using mammalian expression vectors. Pseudotyped virus
particles can also be generated by the expression of the glycoproteins using expression
vectors followed by infection with a virus that does not encode its own glycoproteins.
Like VLPs, pseudotyped virus particles have been used to study the role of various viral
proteins during virus attachment, fusion, and assembly and are being utilized to generate
vaccines that elicit immune responses to the glycoproteins.
Pseudotyped VSV VLPs
Whereas, the expression of influenza matrix (M1) protein has been used as a
means of generating VLPs that can also incorporate glycoproteins from foreign viruses,
VSV matrix (VSV-M) VLPs have not been utilized in the same way, perhaps because
less research has been conducted on them. Nonetheless, non-replicating VSV particles
have been engineered from a recombinant VSV which has its own glycoprotein deleted
(VSVΔG) (143). In situations where the glycoprotein is provided in trans from another
expression system, VSV pseudotyped VLPs have been formed using glycoproteins from
several viruses including influenza C virus (47), measles virus (145), SARS coronavirus
(31), Hantaan and Seoul viruses (105), HBV (128), Andes virus (120), Nipah virus (98),
Ebola virus (143), and human T-cell leukemia virus 1 (106).
Due to the relative safety and easy creation of pseudotyped VSV VLPs, they have
been used in virus entry studies of Andes virus (120), Nipah virus (98), Ebola virus (143),
and human T-cell leukemia virus 1 (106), and measles virus (145) as well as effective
vaccines in animal models for Hantaan and Seoul viruses (78).
Pseudotyped HIV VLPs
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HIV VLPs are easily generated from expression of Gag alone, see above, and
these VLPs can also be pseudotyped with foreign glycoproteins. Generation of
pseudotyped HIV VLPs has been successfully used to generate protective immunity
against influenza virus (51). Additionally, HIV VLPs pseudotyped with influenza HA
(159) and VSV-G (74) have been used in attempts to generate immunity against HIV Gag
in the absence of the immunodominant HIV Env. HIV VLPs co-expressing both HIV Env
and other additional glycoproteins have also been utilized in an attempt to boost the
immune response to Env (45).
Pseudotyped Influenza VLPs
Influenza VLPs can be pseudotyped when VSV-G is co-expressed with either
PB2, PB1, PA, NP, M1, M2, and NS2 (102) or NA, M1, and M2 (77). However, both of
these systems are fairly complex and have not been studied further. Simple pseudotyped
VLP systems are preferred that only require matrix from one virus and glycoproteins
from another. Indeed, influenza VLPs can be generated from the individual expression
of M1 protein, see above. Although some debate in the field on whether M1 was
sufficient has hindered until recently the generation and use of pseudotyped influenza
VLPs. Co-expression of viral glycoproteins from other viruses, along with M1, can result
in their incorporation into the VLPs. When the transmembrane domain and cytoplasmic
tails of the spike glycoprotein from SARS coronavirus is replaced with that from
influenza HA, it can be successfully incorporated into influenza M1 VLPs and
administration in the absence of adjuvant protects mice better than purified spike protein
(Fig 3A) (84). Recently, respiratory syncytial virus (RSV) F and G glycoproteins were
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both successfully pseudotyped onto influenza VLPs and were both able to induce some
protective immunity in mice (Fig 3B) (118).

Pseudotyped Virus Particles
Pseudotyped (or chimeric) virus particles are produced when a glycoprotein from
one virus (glycoprotein donor) is expressed in cells that are infected with another virus
(core donor). The two donor viruses can be from completely different viral families or
simply different strains of the same virus. The core donor can express its own
glycoproteins or can be engineered not to express its own surface proteins. The
expression of donor glycoprotein(s) can be accomplished using several techniques
including transfection with cDNA expression vectors, co-infection with either the donor
virus or an unrelated virus expressing donor glycoprotein, or a recombinant core donor
virus can be engineered to express the donor glycoprotein in addition to or in place of its
own glycoprotein(s).
Pseudotyped VSV Virus Particles
A strain of VSV encoding a temperature sensitive (ts) mutation in the
glycoprotein G has been used to study the ability of glycoproteins from various other
viruses to incorporate into budding particles (30). Rabies virus glycoprotein G was shown
to incorporate into this ts VSV and mediate subsequent infection which could be blocked
by antibodies against rabies G but not VSV-G (155). Co-expression of a fusion of HIV
Env with the cytoplasmic tail of VSV-G, but not of full length HIV Env, can also be
incorporated into this ts VSV when it buds, suggesting that amino acids in the
cytoplasmic tail of VSV-G may interact with matrix and drive incorporation (109, 156).
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Indeed, native Moloney murine leukemia virus (MuLV) glycoprotein is unable to be
incorporated into this ts VSV at non-permissive temperatures (157). The ability to form
rabies G pseudotyped VSV VLPs may relate to the fact that rabies virus and VSV are
both rhabdoviruses and their glycoproteins might share enough sequence homology that
the cytoplasmic tail of rabies G can interact with VSV-M sufficiently to incorporate it
into budding virus particles.
VSV pseudotypes that incorporate VSV-G as well as a foreign viral glycoprotein
have been generated by the co-infection of VSV and many other viruses including
influenza A virus (126), MuLV (157), visna virus (39), lymphocytic choriomeningitis
virus (9), HIV (124), and human T-cell leukemia viruses (21). However, distinguishing
between the two types of virus particles, VSV genome/core or foreign virus genome/core,
can be quite difficult and limits the usefulness of pseudotyped virus particles generated
from co-infections.
The genome of VSV can be engineered to encode extra genetic material and this
has been utilized as a mechanism to express foreign proteins (132). HIV Gag and Env
expressed this way generate their own HIV VLPs but do not get incorporated into the
VSV particles, and therefore do not form VSV pseudotyped virus particles (46). The lack
of incorporation of Env into VSV virus particles could be due to an inherent
incompatibility between the Env and VSV matrix since Env incorporation into VSV can
be induced by deleting three residues from its cytoplasmic tail or replacing the tail with
the VSV-G cytoplasmic tail (62, 63). Similarly, VSV which encodes core, E1, and E2
from hepatitis C virus (HCV) seems to release HCV VLPs but no HCV-pseudotyped
VSV virus particles (2, 26). Like HIV Env, HCV glycoproteins E1 and E2 can be
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incorporated into VSV virus particles by alteration of the cytoplasmic tail, which
removes the ER retention motifs in E1 and E2 (75, 94). Additionally, other full length
viral glycoproteins are able to be incorporated into the wildtype VSV virus particles
including cellular CD4 (131), H and F of measles virus (131), F and G from RSV (66),
GP from Ebola, Marbug, and Lassa viruses (35), and HA and NA from influenza A virus
(73).
More recently, reverse genetics have been used to generate recombinant VSV that
does not encode VSV-G (143). This VSVΔG virus can be generated in cells expressing
VSV-G and when used to infect cells expressing a foreign glycoprotein in trans, nonreplicating pseudotyped VSV VLPs are generated (see above). However, this VSVΔG
can also be engineered to express a foreign glycoprotein in cis by cloning the
glycoprotein into the VSV genome, which generates pseudotyped VSV virus particles.
As long as cells which express the receptor to the foreign glycoproteins are infected, then
the pseudotyped virus particles are able to replicate and produce new pseudotyped virus
particles. This system has been developed for several diverse viruses including influenza
A virus (121), HCV (10), Ebola, Marburg, and Lassa viruses (35), and RSV (65).
Pseudotyped virus particles, have been used as effective vaccines in animal
models when core proteins and genetic material from VSV are encased in lipid
membranes containing glycoproteins from other viruses, including Ebola, Marburg, and
Lassa viruses [(35), reviewed in (27)], as well as Nipah virus (14), HCV (89), and RSV
(65).
Pseudotyped Influenza Virus Particles
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Before the creation of an influenza A virus reverse genetic system, reassortment
of two strains of influenza was used as a mechanism of studying individual genes as well
as a way to generate the yearly vaccine candidates. A reassortant virus that expresses HA
and/or NA from one strain and the core proteins from another strain is essentially a
pseudotyped virus particle. Since influenza A viruses contain 8 genomic segments, a coinfection with two strains could result in 28 or 256 different possible strains. Reverse
genetics has greatly improved the ability of obtaining a virus that encodes glycoproteins
one strain and all other segments from another strain, often referred to as a master donor
strain (Fig 4).
Pseudotyping influenza virus particles is the primary method used every year to
generate both the live attenuated and inactivated annual seasonal influenza vaccines
[reviewed in (29)]. The inactivated seasonal vaccine is currently generated using a
reverse genetics system in which the HA and NA genes from the strains predicted to
circulate in the upcoming influenza season are combined with the 6 other segments from
a high growth donor strain adapted to grow to high titers in eggs, A/Puerto Rico/8/34
(PR8). Likewise, the live attenuated seasonal vaccine is generated using similar
methodology with the exception that the donor strain which provides all segments other
than HA and NA is a cold-adapted, live attenuated strain, A/Ann Arbor/6/60.

Infectious Virus Particles
Infectious virus particles can enter a cell and generate infectious, and sometime
non-infectious, progeny. They are normally generated by the infection of cells with live
virus, but they can also be initially generated several other ways. With many positive
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stranded RNA viruses, transfection of RNA or expression of the RNA from a plasmid can
result in production of infectious virus particles. Reverse genetic systems also exist for
many negative sense RNA viruses where infectious virus can be produced from the
expression of the polymerase genes, either by mammalian expression vectors or nonreplicating helper viruses, along with negative sense viral RNA, either by RNA
transfection or plasmid expression of the viral RNA using polymerase I promoter and
terminators in order to generate ribosomal RNA that lacks both 5’ cap and a 4’ poly(A)
tail (25, 101, 103).
Infectious VSV Virus Particles
Another virus that assembles with a two step process is VSV. However, this
process is different from influenza virus in that both steps, RNA incorporation and
particle formation/release, are directed by one protein, VSV-M. The assembly and
budding of VSV has been studied extensively [some reviewed in (60)]. After
transcription and replication of the single segment of VSV vRNA, the vRNA is bound
and protected by the VSV-N protein to form a ribonucleoprotein complex (RNP) (44,
147). The VSV-M protein has inherent membrane binding capabilities and exists as two
pools in cells, one in the cytoplasm and one at the plasma membrane (79). Membrane
binding by VSV-M can induce membrane curvature and is the only viral protein required
for particle release, see above, but it is insufficient to induce complete budding in the
absence of cellular proteins (137). The binding of VSV-M to the RNPs induces
condensation and formation of the skeleton structure that is found in viral particles (69,
87, 104). This VSV-M interaction with RNPs may be seeded by the presence of the
glycoprotein G (142). Indeed, cryo-electron microscopy models of N-M complexes
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suggest that VSV-N forms the tip of the bullet-shaped viral particle and is only
surrounded and strengthened by VSV-M (37). However, this condensation, incorporation,
and release of particles has been shown in the absence of the glycoprotein G (143). As
was previously noted, expression of M alone can lead to production of VLPs, further
suggesting that VSV-G is not required for production of virus. However, in the absence
of VSV-G, the budding “bald” particles are unable to bind, enter, and infect subsequent
cells since VSV-G is responsible for viral attachment and fusion (143).
VSV buds from microdomains at the plasma membrane which are enriched in the
glycoprotein G (6, 85, 86). Influenza microdomains are similar to lipid rafts in that they
are in enriched in cholesterol, gangliosides glycosphingolipids, and GPI-anchored
proteins and can be extracted due to their low solubility in cold non-ionic detergents such
as TX-100 [reviewed in (136)], whereas VSV microdomains are thought to be
independent of both lipid rafts and CD4-containing microdomains (5, 7). In fact, VSV-G
is often used as a negative control for lipid rafts (162).
VSV-M contains two late motifs [reviewed in (11)], a PPxY late motif, which is
important for virus particle release, interacts with WW domain containing proteins like
Nedd4 (22, 49, 50, 61) and a PSAP late motif that does not appear to be important for
virus particle release (58).
As discussed previously, expression of VSV-G alone, like VSV-M, is sufficient to
induce VLP formation; however, non-infectious virus particles can form in the absence of
G albeit less efficiently (143). Although there are not specific interactions between the
VSV-G cytoplasmic tail and VSV-M (130), VSV-G is nonetheless believed to enhance
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the ability of VSV-M to bind and condense RNPs, thereby slightly enhancing particle
release in the presence of VSV-G (60, 130, 142).
Infectious HIV Virus Particles
HIV assembly and budding occurs in two steps like VSV. However, for HIV, the
first step involves RNA packaging, as well as virus assembly and release, and the second
step involves maturation of the particles. HIV budding is largely driven by Pr55gag, see
above, and the localization of Pr55gag in particular membrane microdomains drives virus
particle assembly and budding from these locations. Therefore, like influenza, VSV, and
many other viruses, HIV buds from a type of membrane microdomains often called lipid
rafts which are enriched in cholesterol, glycosphingolipids, and sphingomyelin [reviewed
in (136, 152)]. Also, similar to influenza, tetraspanins get incorporated into HIV virus
particles and but their role in virus budding is unclear [reviewed in (146)].
In a simplified model of HIV budding, MA directs membrane binding, CA assists
Gag-Gag interactions, NC binds viral RNA, and p6 recruits cellular factors involved in
particle release [reviewed in (34)]. It should be stated that most of these functions of the
Gag proteins are occurring while Pr55gag is uncleaved and, therefore, multiple Gag
domains interact in a highly complex way in order to direct and control the various
budding processes including membrane and RNA binding, oligomerization, and particle
release.
During virus particle release, protease (PR) is activated and cleaves Pr55gag inside
immature particles into several proteins, including matrix (MA), capsid (CA),
nucleocapsid (NC), and p6 [reviewed in (34)]. This cleavage causes structural
rearrangement inside the virion, often called maturation, resulting in the formation of
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infectious, mature particles. After this structural rearrangement there are three distinct
layers inside the viral membrane; MA remains bound to the inside leaflet of the viral
membrane forming an electron dense ring, CA assembles into a conical capsid that sits
inside the MA layer, and NC coats the vRNA and resides in the center of the virions.
Although MA-CA-NC, without p6, can induce VLP formation (see above), p6, in
particular a PTAP late domain within the protein, is required for efficient virus particle
release in the context of virus infection (42, 53). Particles can be released in the absence
of this late domain within p6 if the protease activity of PR is disrupted; however, particles
that bud in this fashion never undergo proteolytic maturation of Pr55gag and are noninfectious (53). The late domain in p6 has been shown to mimic the cellular Hrs protein
in order to bind TSG101, a cellular component of ESCRT-I complex which normally aids
in the cellular vesicle protein sorting pathway, and co-opt it into helping release HIV
virus particles [(36, 92, 113), reviewed in (11)].
The release of HIV virus particles can be restricted by a cellular protein, tetherin,
which can bind both the plasma membrane and the viral membrane and prevent particles
that have undergone scission from being released into the supernatant (99, 151). The
activity of tetherin can be modulated by the HIV protein Vpu which downregulates the
surface expression level of tetherin (99, 151).
Like influenza virus and VSV, HIV virus particles can bud in the absence of
glycoprotein Env expression. However, whereas specific interactions between the matrix
and glycoproteins of the former two viruses have been shown to various extents,
interactions between HIV Env and Gag have never been conclusively proven [reviewed
in (152)]. An interesting model put forth recently based on Ebola pseudotyping of HIV in
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the presence of Env co-expression is that microdomains containing Gag interact with
distinct microdomains containing different glycoproteins thus producing particles with
either HIV Env or Ebola glycoprotein but not both (81). This study suggests that
incorporation of glycoproteins into HIV virus particles may rely more on aggregation of
membrane microdomains rather than direct interactions between Gag and they
glycoproteins.
Infectious Influenza Virus Particles
The assembly of influenza virus particles occurs at microdomains in the plasma
membrane which are enriched in the viral glycoproteins, HA and NA. These
microdomains contain an enrichment of cholesterol and resemble lipid rafts [(80, 129,
162), reviewed in (136)]. M1 interacts with the HA and NA in these sites, potentially
through their cytoplasmic tails (1, 162). M2 is then recruited to the budding site and is
important for viral RNA incorporation (16, 43, 95, 96). The mechanism of M2
recruitment and incorporation is currently under debate. Several potential methods of M2
incorporation have been suggested including ectodomain binding (112), cholesterol
binding (133), and interactions with M1 (16, 95). However, there remain a few issues
with these proposed incorporation mechanisms. The work by Park et al. describing that
the ectodomain of M2 is sufficient to drive incorporation was based upon chimeras
between M2 and the Sendai F protein (112). Because Sendai F has a structure very
different from M2 and many of these chimeras were not expressed at the cell surface,
complete interpretation of the findings is difficult. No research following up this claim
has been published and there are no known interactions between the ectodomains of M2
and the other viral glycoproteins, HA and NA. Schroeder et al. first published that
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cholesterol can bind M2 in vitro and suggested that binding cholesterol that rims the
microdomains where assembly occur could induce M2 incorporation (133). The
remaining hypothesis, interactions between M1 and M2 drive the incorporation of M2,
has been studied but is not yet definitive. Two M1 binding sites within the M2
cytoplasmic tail have been mapped, one in the membrane proximal region (residues 4569) and another in the membrane distal region (residues 70-97) (95, 96). Deletion or
mutation of amino acids in the membrane distal region lead to decreased vRNA
incorporation but do not affect M2 incorporation (16, 43, 95, 96). The mechanism of M2
incorporation and the role the membrane proximal region of the cytoplasmic tail in this
process are the focus of this thesis.
The M2 protein and a peptide corresponding to an amphipathic helix in the
membrane proximal cytoplasmic tail of the protein, have also been shown to induce
membrane curvature and scission in unilamellar vesicles and were suggested to be
necessary for membrane scission and virus particle release (125). However, both VLPs
(16, 17, 40, 68, 76, 77, 117, 140, 150, 160), as discussed above, and virus particles (18,
43, 57) can be released in the absence of M2.
Despite release of virus particles occurring in the absence of M2, various
deletions and mutations in M2, and in particular the cytoplasmic tail, attenuate virus
replication significantly (43, 59, 95, 96) and can be complemented with full length M2
expressed in trans (16, 43, 95, 96). Thus influenza A virus assembly and budding can be
described as two types or steps, similarly to VSV and HIV. Indeed, if M2 is not
expressed, virus particles are assembled and released, but they have a defect in vRNA
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incorporation (Fig 5A) (43). Infectious virus particles are only produced when functional
M2 is expressed and incorporated into the budding particles (Fig 5B) (16, 43, 95, 96).
During virus budding, viral proteins through late domains have often been shown
to redirect cellular proteins to the assembly site to achieve scission [reviewed in (15)].
The sequence YRKL in M1 was proposed as a late domain, but much of that work has
subsequently been retracted (54-56). Additional support that M1 might not contain a viral
late domain comes from the findings that budding of influenza virus particles, as well as
influenza VLPs, have been shown to be VPS4 independent, unlike other viruses which
utilize late domains (8, 17).
Numerous cellular proteins are known to be required for replication, assembly,
and release of influenza A virus. A genome-wide RNAi screen identified that, among
other cellular proteins, a cellular tetraspanin protein, CD81, was necessary for influenza
virus replication (71). Both CD81 and tetraspanin CD9 have also been identified in
purified influenza virus particles (135). However, further research will be required to
identify how CD81 and possibly other tetraspanins are necessary for virus replication.
Another cellular factor that affects the budding of various viruses is tetherin. However,
the ability of tetherin to restrict influenza budding has not yet been fully elucidated. The
budding of VLPs containing only NA is tetherin restricted in one strain of influenza virus
but not another (160). However, a recent report suggested that infectious influenza virus
particles expressing tetherin-restricted NA are not themselves restricted by tetherin (153).
It may very well turn out that some influenza VLPs but not influenza virus can be
restricted by tetherin, but in the latter paper, the assays used to compare virus and VLP
restriction were completely different, stable expression of tetherin in MDCK cells or
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transient over-expression in 293T cells, respectively. Additionally, electron micrographs
of infected 293T cells clearly show elongated viral particles when tetherin is transiently
expressed, a defect not seen when other viruses are restricted by tetherin. Nonetheless,
this suggests that transient tetherin expression in 293Ts can restrict influenza virus and
influenza VLPs. However, more work needs to be done to clearly elucidate which, if any,
strains of influenza virus are restricted by tetherin during infection or VLP formation.
Additional experiments should also determine the average length of influenza virus
particles released from 293T cells in the presence and absence of tetherin.

Concluding Remarks
Non-enveloped VLPs
Although this discussion has focused on enveloped particles, it is noteworthy that
VLPs can also be produced by the expression of proteins from non-enveloped viruses.
Two licensed, VLP-based human papillomavirus vaccines are on the market, Cervarix
from GlaxoSmithKline and Gardasil from Merck, which are produced from the
expression of L1 from baculovirus and yeast cells, respectively [reviewed in (111)].
Expression of some enveloped virus capsid proteins can also generate non-enveloped
VLPs. Natural infection with hepatitis B virus (HBV) results in the production of subviral
particles (essentially VLPs) which can be used to generate protective immune responses.
Recombinant versions of HBV VLPs are currently licensed by several manufacturers
[reviewed in (122)].
Summary of VLPs and Infectious Virus Particles
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The differences between VLPs, pseudotyped VLPs, pseudotyped virus particles,
and infectious virus particles have been carefully defined in this review. However, the
literature sometimes uses some of the terms interchangeably. Nonetheless, VLPs remain
a valuable tool for dissecting virus biology, but results found with them should always be
confirmed in the context of infectious virus particles. Pseudotypes, in particular
pseudotyped VLPs, remain promising vaccine platforms. Similarities and differences
between infectious virus particles will continue to be revealed.

Goals of the Thesis
The primary aim of this thesis was to determine the role of the membrane
proximal region of the M2 cytoplasmic tail in virus replication. It was known previously
that this region was able to bind M1 (95), was able to bind cholesterol in vitro (133), and
that deletion of the rest of the M2 cytoplasmic tail still allowed incorporation of M2 (96).
Through a series of experiments that I proposed, I sought to investigate the various
aspects of the membrane proximal region of M2. Mutant proteins were investigated using
mammalian expression systems, a trans-complementation system, and recombinant
viruses. I determined that the M2 cholesterol binding motif is not required for virus
replication in tissue culture but viruses lacking the motif caused less morbidity and
mortality in mice. I additionally established that the membrane proximal residues
tolerated numerous mutations with little, if any, affect on virus replication suggesting that
the protein structure of this region, rather than the identity of individual amino acids, may
be critical for M2 protein function. Chimeric proteins between influenza A virus M2 and
an M2 homolog in influenza C virus, CM2, were also utilized to compare the ion channel
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function of the two proteins. I further confirmed that residues in the ectodomain and
cytoplasmic tail of M2 are important in the assembly of infectious influenza A virus.
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Figure Legends

Figure 1. Composition of various enveloped particles produced by the expression of
viral proteins. A) The expression of viral glycoproteins and/or internal core proteins can
induce the formation of virus-like particles (VLPs). B) The co-expression of
glycoproteins from one or more distinct viruses during the production of VLPs from
another virus can produce pseudotyped virus-like particles which may contain
glycoproteins and/or core proteins from one virus along with glycoproteins from other
viruses. C) Pseudotyped virus particles are produced by the co-expression of
glycoproteins from distinct viruses in cells infected with another virus. D) Infectious
virus particles are the product of natural virus infections and are characterized by a
complete viral genome and complement of viral proteins. Natural infections can
sometimes also produce incomplete virus particles that are non-infectious, not shown. In
pseudotypes, foreign glycoproteins are shown in blue and yellow and, in all particles,
proteins from the parental virus are shown in red.

Figure 2. Influenza virus-like particles (VLPs). A-D) Depending on the particular
expression system and strain of influenza A virus, M1 (A), M2 (B), HA (C), or NA (D)
expression alone has been shown to be sufficient to induce VLP budding and release. EH) Various influenza A VLPs which have been shown to induce various levels of protect
immunity in immunized animals include ones generated from the expression of M1 and
M2 (A); M1 and HA (B); M1, HA, and NA (C); and M1, HA, NA, and M2 (D).
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Figure 3. Pseudotyped influenza VLPs. Foreign glycoproteins can be incorporated into
influenza VLPs when co-expressed with M1 using a baculovirus expression system. A)
The ectodomain of SARS coronavirus spike (S) protein fused to the transmembrane
domain and cytoplasmic tail of influenza HA and B) the native glycoproteins G and F
from RSV can be incorporated into influenza VLPs

Figure 4. Pseudotyped influenza virus particles. Pseudotyping influenza viruses is
utilized to generate influenza vaccines candidates. Either by co-infection or reverse
genetics, the HA and NA glycoproteins from a glycoprotein donor strain are combined
with all the proteins expressed by the other 6 segments from a core donor strain to
generate a pseudotyped influenza virus particle.

Figure 5. Infectious influenza virus particles. A) If M2 is not expressed, virus particles
assembly and are released, but they have a defect in viral RNA (vRNA) incorporation
and viral infectivity. B) If functional M2 is expressed, infectious virus particles are
formed that incorporate M2 and vRNA.
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Figure 1. Composition of various enveloped particles produced by the expression of
viral proteins.
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Figure 2. Influenza virus-like particles (VLPs).
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Figure 3. Pseudotyped influenza VLPs.
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Figure 4. Pseudotyped influenza virus particles.
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Figure 5. Infectious influenza virus particles.
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CHAPTER 2

The cholesterol recognition/interaction amino acid consensus motif of the influenza
A virus M2 protein is not required for virus replication but contributes to virulence

This chapter is reprinted here essentially as published.
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Abstract
Influenza A virus particles assemble and bud from plasma membrane domains enriched
with the viral glycoproteins but only a small fraction of the total M2 protein is
incorporated into virus particles when compared to the other viral glycoproteins. A
membrane proximal cholesterol recognition/interaction amino acid consensus (CRAC)
motif was previously identified in M2 and suggested to play a role in protein function.
We investigated the importance of the CRAC motif on virus replication by generating
recombinant proteins and viruses containing amino acid substitutions in this motif.
Alteration or completion of the M2 CRAC motif in two different virus strains caused no
changes in virus replication in vitro. Viruses lacking an M2 CRAC motif had decreased
morbidity and mortality in the mouse model of infection, suggesting that this motif is a
virulence determinant which may facilitate virus replication in vivo but is not required for
basic virus replication in tissue culture.
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Introduction
Influenza A virus remains a major public health burden and potential pandemic
threat even with widespread annual vaccination and the availability of antivirals. The M2
protein is required for several steps in the viral life cycle (reviewed in (28)). Following
hemagglutinin (HA)-mediated virus-cell membrane fusion, the ion-channel activity of
M2 is activated in acidified endosomes. M2 translocates protons into the core of the virus
particle which mediates the release of viral ribonucleoprotein (vRNP) complexes from
their association with matrix (M1) protein and viral membranes. The vRNP are
tranported to the nucleus where viral transcription and genome replication occurs. The
ion-channel activity of M2 also raises the pH of the Golgi compartment, thereby
preventing the low pH induced conformational changes in HA proteins which are
processed to their fusion-competent forms by intracellular proteases. Virus particle
assembly occurs at the plasma membrane and the cytoplasmic tail of M2 is required for
efficient incorporation of vRNP into infectious virus particles (19, 20).
Influenza A virus particles assemble and bud from plasma membrane domains
enriched with the viral glycoproteins, HA and neuraminidase (NA). These domains may
also reflect lipid rafts (15, 32, 45). The cytoplasmic tails of HA and NA bind and recruit
M1 to membranes (1). Even though M2 is not found at these sites of glycoprotein
enrichment, a small amount of M2 is incorporated into virus particles (15, 45).
Additionally, the amount of M2 incorporation can be increased if the glycoproteins are
targeted away from lipid microdomains by the deletion of their cytoplasmic tails (3).
Several mechanisms have been hypothesized to contribute to M2 virion
incorporation, including random incorporation and incorporation via interaction with
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cholesterol (34). A membrane proximal cholesterol recognition/interaction amino acid
consensus (CRAC) motif has been identified in the peripheral-type benzodiazepine
receptor and other proteins known to bind cholesterol (16), including caveolin-1 (6) and
human immunodeficiency virus (HIV) gp41 (8, 39, 40). The CRAC motif in gp41 is
adjacent to a transmembrane helix and has been shown to bind cholesteryl-hemisuccinate
agarose (39). Mutation of the motif decreased cholesterol binding but also altered
fusogenic activity when introduced into HIV (4, 40). Schroeder et al. identified a putative
CRAC motif in M2 and determined that M2 protein purified from a baculovirus
expression system binds cholesterol (34). A second CRAC motif immediately
downstream of the first one is present in a limited number of influenza virus strains. They
suggest that cholesterol-bound M2 protein may be able to either rim or unite lipid
microdomains, thereby facilitating M2 incorporation into virions. Because M2 is required
during several distinct steps in the virus life cycle, we investigated the importance of the
CRAC motif on virus replication by generating recombinant proteins and viruses
containing alterations in this motif.

Results
Oligomerization and expression of mutant M2 proteins in stable cell lines.
Influenza A/WSN/33 (rWSN) encodes an M2 protein with a consensus (L/V-X(1-5)-Y-X(15)-R/K

) CRAC motif ((13, 14, 16, 17), reviewed in (5)) while A/Udorn/72 (rUd) encodes

a protein with an R at position 54 which disrupts the consensus (Figure 1). These
influenza virus strains do not possess a second putative CRAC domain (34). Mutations
were made in rWSN M2 to alter the CRAC motif by either mutating residue 54 from
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arginine to phenylalanine (rWSN M2 R54F), the amino acid found in the rUd M2
protein, or changing all of the critical CRAC motif residues to alanine (rWSN M2
delCRAC) in order to eliminate the consensus sequence. Additionally, the CRAC motif
in rUd M2 was completed by mutating residue 54 from phenylalanine to arginine (rUd
M2 F54R). The WSN M2 proteins also contain an asparagine to serine mutation at
residue 31 which conveys amantadine sensitivity (9, 36) so that the potentially toxic
effects of ion channel activity could be inhibited during routine cell culture.
Stably transfected MDCK cell lines were generated which constitutively express
the wildtype or mutant M2 proteins. Mutation of the CRAC motif does not affect M2
protein oligomerization as determined by non-reducing SDS-PAGE and Western blotting
(Fig 2A and D). To determine if the mutant M2 proteins were expressed at the cell
surface, flow cytometry was performed on live cells using an antibody which recognizes
the extracellular domain of M2. Greater than 90% of the cells express M2 at the cell
surface (Fig 2B and E). The total amount of mutant M2 expressed in the stable cell lines
was comparable to a control cell line expressing wildtype M2 protein (Fig1A and D) as
was the amount of M2 expressed at the cell surface (data not shown).
M2 proteins with altered CRAC motifs are able to complement M2 deficient
viruses. The M2 protein plays several roles in the virus life cycle and altering any of
these functions can drastically reduce virus replication and fitness (12, 19, 20, 36). The
ability of stably expressed M2 to complement M2 deficient viruses has been previously
used to study mutations in M2 which may prevent the rescue of recombinant viruses (2,
19, 20, 37). To determine if M2 proteins with mutations in the CRAC motif are able to
complement M2 deficient viruses, stable cell lines expressing M2 were infected with
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viruses which contain a stop codon in their M2 gene (M2Stop viruses). Neither alteration
of the CRAC motif (Fig 2C) nor completion of the CRAC motif (Fig 2F) resulted in a
statistically significant change in the production of infectious virus when compared to wt
M2, indicating all the mutated M2 proteins are fully functional in this assay.
Alteration of M2 CRAC motif does not affect the replication of recombinant
influenza A viruses in tissue culture. In order to confirm that mutation of the CRAC
motif in the M2 protein does not affect virus replication, recombinant viruses were
generated which encode M2 proteins with mutations in the CRAC motif (Figure 1).
Infection of MDCK cells with these viruses results in a similar level of cell surface M2 as
determined by flow cytometry (Fig 3A and D). Multistep growth curves in MDCK (Fig
3B and E) and the human lung adenocarcinoma, CaLu-3 cells (Fig 3C and F) results in no
statistically significant changes in either replication kinetics or peak infectious virus
titers, indicating the recombinant viruses with altered M2 CRAC motifs maintain the
ability to replicate in these cell lines.
Many primary and some laboratory-adapted influenza A virus strains produce
filamentous particles, including rUd, while most laboratory-adapted influenza A virus
strains, such as rWSN, produce spherical particles (22, 29, 30). In order to determine if
completion of the CRAC motif in Ud M2 affects the ability of recombinant virus to
produce filamentous particles, confocal microscopy was performed to compare the
number of infected cells which produce filaments. Filaments formed by both rUd M2
F54R and wildtype were similar in appearance (Fig 4A and B) and the number of
infected cells showing filaments was not significantly different (Fig 4C). Additionally,
like wildtype rWSN, rWSN M2 R54F and rWSN M2 delCRAC failed to formed
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filaments on the surface of infected cells (data not shown). In order to determine if the
filamentous virus particles were similar in size and structure, transmission electron
micrographs were taken of infected MDCK cells. The rUd virus encoding M2 F54R was
able to produce filamentous particles like wildtype virus (Fig 4D and E). Together, this
data indicates that completion of the CRAC motif does not alter the ability of influenza
virus to produce filamentous virus particles.
Virion protein composition of recombinant viruses encoding M2 CRAC
mutants. In order to investigate the requirement of the CRAC motif for incorporation of
viral proteins into virions, virus particles were collected and concentrated through a 20%
sucrose cushion by ultracentrifugation. Virus pellets were resuspended and the amount of
incorporated viral proteins was determined by Western blot (Fig 5A and B). Relative
amounts of full length M2 and total M2 were quantified from replicate experiments. Total
M2 incorporated into either CRAC altered or CRAC completed recombinant viruses was
not statistically different from wildtype (Fig 5C and D). There was a statistically
significant decrease in the amount of truncated M2 protein incorporated into rWSN M2
R54F virions. The truncated form of M2 is thought to be generated via cleavage by
caspases at the C-terminus of M2 but this cleavage does not appear to affect viral
replication (46, 47). Additionally, HA, NP, and M1 were incorporated into virus particles
at levels indistinguishable from wildtype M2when the CRAC motif was altered or
completed (Fig 5A and B; data not shown).
Decreased morbidity and mortality in mice infected with recombinant
viruses expressing M2 CRAC mutants. Some M2 mutations have been shown to have
no effect in vitro but display decreased in vivo pathogenesis (7, 41, 42). In order to
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determine if mutation of the M2 CRAC motif affects in vivo pathogenesis, mice were
infected with rWSN viruses expressing the wildtype M2, M2 R54F, or M2 delCRAC.
When intranasally inoculated with 103 TCID50, mice infected with all viruses displayed
similar survival (Fig 6A). When mice were infected with 105 TCID50 of virus, rWSN
caused significantly more mortality compared to rWSN M2 R54F and rWSN M2
delCRAC (Fig 6B). The median time of death for rWSN (7 days) and rWSN M2 R54F
(11 days) differed as well. Change in body mass induced by infection with 103 TCID50 of
either rWSN or rWSN M2 R54F was more significant than that induced by rWSN M2
delCRAC (Fig 6C). Mice infected 105 TCID50 of the viruses did not display significant
differences in loss of body mass over the first 6 days of infection, despite the decreased
mortality of mice infected with the CRAC altered recombinant viruses (Fig 6D).
Infection of mice with 105 TCID50 of rUd M2F54R did not result in a significant increase
in virus replication or morbidity when compared to rUd, suggesting that restoration of the
complete CRAC domain did not enhance in vivo replication of rUd (data not shown).
This data indicates that elimination of the M2 CRAC motif leads to a modest attenuation
of virus virulence in the mouse model of infection despite no obvious defects in in vitro
virus replication.
Alteration of the M2 CRAC motif does not affect replication of recombinant
influenza A viruses in mTEC cultures. Given the discrepancy between the ability of the
recombinant viruses to replicate in tissue culture cells and their attenuation in the mouse
model of infection, we investigated whether virus infection of mTEC cultures would
better reflect the in vivo virus phenotypes. These primary cell cultures are differentiated
into cell types normally found in the mouse trachea and therefore represent a faithful
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tissue culture surrogate for virus infection of the airways (11, 24, 27). There was no
statistically significant difference in the replication of the mutant viruses in mTEC
cultures as compared to the corresponding wildtype virus (Fig 7), suggesting that
replication in mTEC cultures was not compromised by altering the CRAC motif.

Discussion
This study sought to investigate the role of the CRAC motif found in the M2
protein of two influenza A virus strains. The R54F mutation in the WSN M2 protein was
made to mimic the amino acid found at that residue in Ud M2. The rWSN M2 R54F
mutant virus still contains a putative consensus CRAC sequence because it has another
basic amino acid at residue 56. This could explain why this virus has an intermediate
change in virulence when compared to rWSN and rWSN delCRAC. Mutation of WSN
M2 to either R54F or delCRAC leads to no changes in virus replication in vitro.
Likewise, completion of the CRAC motif in the Ud M2 protein also has no effect on
virus replication in MDCK cells, CaLu-3 cells, or in mTEC cultures. Together, this
suggests that the CRAC motif is not required for in vitro replication of influenza A virus.
Even though the CRAC motif is not essential for in vitro virus replication,
mutation of the motif resulted in decreased morbidity and mortality when mice were
infected with a virus lacking the CRAC motif. The decreased pathogenesis of mutants
may suggest that the CRAC motif of the M2 protein may be a virulence determinant in
that it is not required for in vitro virus replication but is critical for efficient virus
infection in animal models. It is also possible that presence of a complete CRAC motif in
M2 protein contributes to virus infection of other cell types such as alveolar epithelial
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cells or macrophages. Rossman et al. recently demonstrated that amino acids outside of
the CRAC domain contribute to the cholesterol binding of M2 and mutation of these
amino acid sequences leads to decreased in vitro replication (31). The M2 protein only
showed cholesterol binding activity in the context of a virus infection and changes at
multiple amino acids that line the hydrophobic face of a membrane proximal alpha helix
of the protein were demonstrated to be critical for in vitro virus replication. This suggests
that the CRAC motif in and of itself, is not required for influenza virus replication in
vitro, a fact supported by our data.
The cytoplasmic tail of M2 has been implicated in the stabilization of the open
state of the M2 ion channel (33, 38), virion incorporation of M1 and vRNP (12, 19, 20),
virus morphology (12), and virus infectivity (2, 12, 19, 20, 36). Although the
transmembrane domain of M2 has been studied by NMR and crystallography, the
structure of the cytoplasmic domain is less well understood (33, 35). The structure of
residues 45-60 of the M2 cytoplasmic tail has been determined by NMR in concert with
the transmembrane domain (33), but the structure of the entire cytoplasmic tail has yet to
be determined. Residues 47-50 form a short, flexible loop linking the transmembrane
domain to a C-terminal amphipathic helix (residues 51-59) that forms a stable “base”
important for holding the tetramers together during the conformational changes
associated with ion channel activation. The CRAC domain and a site for palmitoylation
(Ser 50) fall into these regions and it has been speculated that these modifications may
stabilize the interaction of the M2 cytoplasmic tail with lipid membranes (33).
Elimination of the CRAC motif or the M2 palmitoylation site (7) does not alter virus
replication in vitro, but does yield viruses that are attenuated in the mouse model of
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infection. This data argues against a critical role for these two sequences in virus
replication, though both sequences are essential for maintaining virus virulence in vivo.
While these sequences may be dispensable for virus replication, this does not imply that
this region of the M2 protein is not important for M2 function either as a structural motif,
or through properties as yet undefined.
The CRAC motif in the M2 protein is not required for incorporation of M2 into
virions, nor does it affect the incorporation of other viral proteins. Alternate methods
mediating the incorporation of M2 into virions must therefore exist. One study suggests
that the ectodomain of M2 can drive a foreign protein to be incorporated into influenza A
virus particles (26) but there are no known interactions between the M2 ectodomain and
the ectodomains of the other viral glycoproteins. The mechanism by which a limited
amount of M2 is incorporated into virus particles despite the high amounts of M2 located
in the plasma membrane but not in the same membrane microdomains as the
glycoproteins remains to be determined.

Materials & Methods
Plasmids. The plasmid pCAGGS (25) was used for M2 expression in mammalian
cells. A plasmid expressing the M2 cDNA from influenza A/Udorn/72 (Ud M2) has been
described previously (20). The M2 coding region from influenza A/WSN/33 (Genebank
Accession number ABF21317) was amplified by RT-PCR and cloned as described
previously for M2 Ud (18). A WSN M2 cDNA encoding a protein sensitive to the
antiviral drug amantadine was constructed by changing the amino acid at position 31
from arginine to serine (N31S) (36). All M2 mutations were introduced into the
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expression plasmids by overlap extension PCR and the sequences of the mutated
plasmids were confirmed. Primer sequences are available upon request.
The pBABE plasmid, which expresses puromycin N-acetyltransferase, was used
to generate stable cell lines expressing mutant M2 proteins as previously described (21).
In order to generate recombinant influenza viruses expressing M2 proteins with
altered CRAC motifs, mutations were introduced into the pHH21 M segment plasmids
via site-directed mutagenesis (Stratagene). The sequence of the entire M segment of the
resulting plasmid was confirmed.
Cells. Madin-Darby canine kidney (MDCK) cells, human lung adenocarcinoma
(CaLu-3) cells (ATCC HTB-55), and human embryonic kidney (293T) cells (36) were
cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS, Atlanta Biologicals), 100U/mL penicillin (Invitrogen), 100μg/mL
streptomycin (Invitrogen), 1mM sodium pyruvate (Sigma), and 2mM GlutaMAX
(Invitrogen). Cells were maintained at 37°C in a humidified 5% CO2 environment.
Generation of stable cell lines. MDCK cells stably expressing M2 proteins were
generated as described previously (20). Briefly, MDCK cells were cotransfected in
suspension with 1μg pCAGGS M2 expression plasmid and 0.5μg pBABE puromycin
expression plasmid using 9μL of Lipofectamine 2000 (Invitrogen) as per the
manufacturer’s protocol. Cells were plated into 6 well plates, selected using 7.5μg/mL
puromycin dihydrochloride (Sigma), and single colonies were isolated and expanded.
Expression of M2 was confirmed by indirect immunofluorescence staining of surface M2
using monoclonal antibody (MAb) 14C2. M2 expressing cells were maintained with 5μM
amantadine hydrochloride (Sigma).
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Viruses. The viruses used in this study were rWSN and rUd (recombinant
versions of A/WSN/33 and A/Udorn/72, respectively). Viruses were generated using a
12-plasmid rescue system described previously (19, 20, 23, 36). The entire coding region
of the M segment sequence of all rescued viruses was confirmed. There were no
discernable differences in plaque size or morphology between any of the recombinant
viruses (data not shown).
Virus growth curves were performed at a multiplicity-of-infection (MOI) of
~0.001. For complementation assays, MDCK cells expressing mutant M2 proteins were
infected with recombinant viruses that were functionally deleted for the expression of M2
(M2stop viruses) as described previously (19). For recombinant viruses, mutant M2expressing viruses were used to infect MDCK or CaLu-3 cells. Cells were infected by
twice washing confluent 6 well plates of MDCKs with phosphate buffered saline (PBS,
Invitrogen) then infecting with the indicated viruses in 500μL infectious media (DMEM
supplemented with 5% bovine serum albumin (BSA, Calbiochem), 100U/mL penicillin,
100μg/mL streptomycin, 2mM GlutaMAX, and 4μg/mL N-acetyl trypsin (NAT, Sigma))
at room temperature with rocking for 1hr. Cells were then washed twice with PBS and
incubated with 500μL infectious media. Media was removed and replaced with fresh
media at the indicated timepoints. Infectious virus titers were quantified by determining
the 50% tissue culture infectious dose (TCID50) on MDCK cells (for M2-expressing
viruses) or MDCK cells expressing WSN M2 N31S (for M2Stop viruses). Media lacking
trypsin was used for infection of CaLu-3 cells. Standard error of the mean is graphed
from infections done in duplicate or triplicate. The experiments were repeated at least
twice and one representative example is graphed.
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For microscopy, MDCK cells were grown to confluency on tissue culture treated
glass coverslips and media changed every 2 days. Four days after confluence, cells were
washed twice with PBS, infected with 500,000 TCID50 (~0.9 MOI) of the indicated virus
in 500μL medium for 1 hr at room temperature. Cells were then washed, the media was
replaced and the cells incubated at 37C for 15 hours.
Virus purification. Virus particles were isolated from the supernatants of MDCK
cells infected at an MOI of 5 for 15hr. Cell debris was removed by centrifugation at 1,900
g for 10min at 4°C. Virus particles were then concentrated through a 20% sucrose
cushion with centrifugation at 118,000 g in a TH641 rotor (Sorval) for 1hr at 4°C. Virus
pellets were resuspended in 100μL PBS and mixed 1:1 in 2x SDS-PAGE sample buffer.
SDS-PAGE and Western Blotting. MDCK cells were lysed in 1% SDS (Fisher
Scientific) in PBS and mixed 1:1 in 2X SDS-PAGE sample buffer. Polypeptides were
resolved on 17.5% polyacrylamide gel with 4M urea and transferred to polyvinylidene
difluoride membranes (PVDF, Millipore). Membranes were blocked with PBS containing
0.3% Tween-20 (Sigma) and 5% dry milk, incubated 1hr RT with primary antibody,
washed three times with PBS with 0.3% Tween-20, incubated 1hr RT with secondary
antibody, and washed four times with PBS containing 0.3% Tween-20. The primary
antibodies used were mouse α-M2 14C2 MAb (1:1,000 dilution) (44), mouse α-M1 HB64 MAb (1:100 dilution) (20, 43), mouse α-NP HB-65 MAb (1:100 dilution) (20, 43),
goat α-A/Udorn/72 serum (1:500 dilution) (45), or goat α-HA0 A/PR/8/34 (1:500
dilution, V-314-511-157; National Institute of Allergy and Infectious Diseases).
Secondary antibodies were goat α-mouse immunoglobulin G (IgG) conjugated to
AlexaFluor 647 (4μg/mL, Invitrogen), donkey α-mouse IgG conjugated to AlexaFluor
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647 (4μg/mL, Invitrogen), donkey α-goat IgG conjugated to AlexaFluor 647 (4μg/mL,
Invitrogen). Membranes where then scanned using an FLA-5000 (FujiFilm), samples
were normalized to total M1 and M2 expression relative to wild type protein was
determined. Structural proteins and oligomeric forms of M2 are indicated.
Flow Cytometry. Cells were removed from the tissue culture plates with trypsin
treatment. The trypsin was inactivated with serum containing media and cells were
washed once with PBS and incubated on ice for 30min, in the presence of blocking buffer
(PBS supplemented with 0.5% BSA and 3% normal goat serum (NGS, Sigma)). Cells
were then incubated for 1hr on ice with an antibody that recognizes the M2 ectodomain
(14C2 MAb, 1:1000 dilution), washed three times with PBS, incubated with goat αmouse IgG conjugated to AlexaFluor 488 (4μg/mL, Invitrogen) for 1hr on ice, and
washed three times with PBS. Cells were then fixed with 1% formaldehyde (Fisher
Scientific) in PBS for 15min at room temperature. The cells were analyzed on a
FACSCalibur (Beckton Dickinson) and quantified using FlowJo software (Tree Star). All
antibody dilutions were made in blocking buffer.
Microscopy. The cells were treated as for flow cytometry except antibodies were
goat α-H3 sera raised against A/Aichi/2/68 (1:500 dilution, V-314-591-157; National
Institute of Allergy and Infectious Diseases) and donkey α-goat IgG conjugated to
AlexaFluor 555 (4μg/mL, Invitrogen). After incubation with antibodies, the cells were
fixed with 2% paraformaldehyde (Sigma) in PBS for 15min at room temperature, washed
twice with PBS, then mounted on slides using ProLong Gold anti-fade (Invitrogen).
Samples were imaged on a Nikon Eclipse 90i microscope. For quantification, 10 or 20
images of random fields of view were taken with a 20x objective in two separate
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experiments. For each image, the number of infected cells and cells with filaments were
counted and used to determine the percentage of infected cells expressing filaments. Data
from one representative experiment is shown. For high magnification images, Z-sections
were taken at 0.3μm intervals on a Leica 510 Meta LSM confocal microscope using a
100x oil-immersion lens. Volocity 3D imaging software (Improvision) was used to
analyze and flatten Z-sections.
Transmission Electron Microscopy. MDCK cells were grown to confluency in
3.5cm dishes and infected at an MOI of ~5 with either rUd or rUd M2 F54R. At 10hpi,
cells were washed twice with PBS and fixed with 2mL of fresh fixative (2%
glutaraldehyde, 0.1M cacodylate, 3% sucrose, and 3mM CaCl2 in PBS pH7.4) overnight
at 4°C. Cells were post-fixed with 1% osmium tetroxide reduced in potassium
ferrocyanide for 1 hr at 4°C. After fixation, cells were stained en bloc with a 2% aqueous
solution of uranyl acetate and dehydrated in graded ethanol. Embedding was done in
Eponate 12 Resin (Ted Pella). Thin sections (70-90nm) were cut on a Reichert-Jung
Ultracut E and placed on 200 mesh copper grids. The sections were stained with uranyl
acetate and lead citrate and viewed on a Hitachi 7600 TEM with an AMT digital camera.
Infection of BALB/c mice. Six to 8-week old female BALB/c mice (Charles
River) were used as described previously (24, 42). Mice were anesthetized and
administered an intranasal inoculation of 103 or 105 TCID50 of rWSN, rWSN M2 R54F,
or rWSN M2 delCRAC virus diluted in 20μL DMEM supplemented with 100U/mL
penicillin, 100μg/mL streptomycin, and 4μg/mL NAT. Animals were monitored for 14
dpi for morbidity and mortality (42). Changes in body mass are graphed as percent of
starting mass.
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Infection of mTEC cultures. Mouse tracheal epithelial cells (mTECs) were
harvested, isolated, and differentiated as described previously (10, 24). Cultures were
infected via the apical chamber with 3,300 TCID50 in 100μL of media, ~0.01 MOI
assuming all cells are susceptible to infection. After 1hr, apical supernatants were
removed and replaced with fresh media. At the indicated hpi, apical and basolateral
supernatants were removed and replaced with fresh media. Throughout the infection,
infectious media without NAT was used. Infectious virus titers were quantified at
indicated times as above. Standard error of the mean is graphed from infections done in
duplicate.
Statistical Analysis. Infectious virus production and body mass changes were
analyzed using mixed ANOVAs with time and virus as the independent variables. Protein
concentrations and differences in the percentage of cells with filaments were calculated
using t-tests. Mean day of death was determined by logrank test. Significant interactions
were further evaluated using the Tukey method for pairwise multiple comparisons.
Statistically significant differences of p<0.05 (*) or p<0.01 (**) are indicated and all
analyses were done with Prism 4.0 (GraphPad Software Inc.).
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Figure Legends

Figure 1. Sequence alignment of M2 residues 46-56. The amino acids that define the
CRAC motif are in bold and substitutions that disrupt or complete the consensus are
indicated. An asterisk indicates no change in sequence. The rWSN M2 R54F mutant still
contains a potential CRAC consensus sequence due to the presence of another basic
amino acid at position 56.

Figure 2. Expression and function of M2 proteins with modified CRAC motifs. (A
and D) MDCK cells expressing the indicated M2 proteins were analyzed by Western
blotting to detect disulfide linked oligomeric forms of the M2 protein. Monomers, dimers
and trimers are indicated and some higher order oligomers can be detected. (B and E) The
number of cells expressing M2 at the cell surface was quantified by flow cytometry from
the indicated stably transfected MDCK cell lines. (C and F) The ability of the indicated
stably transfected MDCK cells to complement infection with a recombinant influenza
virus that does not encode the full length M2 protein was assessed by infecting the cells
with the indicated recombinant virus and quantifying infectious virus production at
various hours post infection (hpi). The average and standard error of the mean are
graphed. The standard error is smaller than the size of the individual points. The limit of
detection is marked by a dotted line. Proteins or recombinant viruses based on the rWSN
(A-C) and rUd virus strains (D-F) were used.
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Figure 3. The effects of altering the CRAC motif on replication in tissue culture. (A
and D) MDCK cells were infected with the indicated viruses at an MOI of ~3 and the cell
surface expression of M2 protein was measured by flow cytometry at 15 hours post
infection (hpi). The relative expression of M2 represents the mean channel fluorescence
of the indicated infected cells divided by the mean channel fluorescence of the wildtype
infected cells. MDCK (B and E) or CaLu-3 (C and F) cells were infected at an MOI of
~0.001 with the indicated recombinant viruses. At the indicated hpi, infected cell
supernatants were harvested and the number of infectious virus particles determined by
TCID50 assay. Data points represent the average and standard error of the mean. The
horizontal dotted line is the limit of detection.

Figure 4. The effects of completing the CRAC motif on formation of filamentous
virus particles. MDCK cells were infected with 500,000 TCID50 (~0.9 MOI). At 15hpi,
immunofluorescence staining was performed for HA and visualized by confocal
microscopy. Confocal Z-sections (taken with a 100x objective) of rUd (A) or rUd M2
F54R (B) infected cells were flattened and show viral filaments for both viruses. The
percentage of infected cells showing filaments was determined from 10-20 images taken
with a 20x objective on an epifluorescence microscope (C). One representative
experiment is shown. For TEM, MDCK cells were infected at an MOI of ~5. Samples
were processed for transmission electron microscopy at 10 hpi. Cells were infected with
rUd (D) or rUd M2 F54R (E). Arrows indicate microvilli, solid arrowheads indicate
filamentous virus particles, and empty arrowheads mark either spherical virus particles or
cross-sections of filamentous virus particles.
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Figure 5. The effects of altering the CRAC motif on incorporation of structural
proteins. MDCK cells were infected with the indicated viruses at an MOI of 5. At 15hpi,
virus particles were collected and concentrated through a 20% sucrose cushion at 118,000
g for 1hr. Virus pellets were resuspended and incorporation of viral proteins was
determined by Western blot with antibodies which detect the structural proteins HA, NP,
M1, and M2. (A and B) Representative Western blots showing incorporation of viral
proteins into virions. (C and D) Quantification of full length M2 and total M2 from
Western blot analysis of replicate virion incorporation assays. Increased contrast was
used on the Western blot of virion-associated proteins to allow for detection of low
intensity bands. Relative expression was determined by the negative log of M1
normalized data. Recombinant viruses based on the rWSN (A and C) or rUd virus strains
(B and D) were used. * = p<0.05.

Figure 6. Mortality and morbidity of mice infected with recombinant influenza
A/WSN/33 viruses encoding M2 proteins with altered CRAC motifs. Mice were
administered an intranasal dose of 103 (A and C) or 105 (B and D) TCID50 of the
indicated viruses and monitored for 14 days post infection (dpi). (A and B) Mortality and
(C and D) morbidity associated with infection, as judged by loss of starting weight. Data
points indicate the average and standard deviation. Significant differences in (B) are
between the CRAC altered viruses and rWSN while in (C) the differences are between
rWSN M2 delCRAC and the other two viruses. * = p<0.05 and ** = P<0.01.

78

Figure 7. The effects of altering the CRAC motif on replication in mouse tracheal
epithelial cell (mTEC) cultures. mTEC cultures were infected with 3300 TCID50 (~0.01
MOI) of the indicated recombinant viruses in the rWSN (A) or rUdorn (B) genetic
backgrounds. At the indicated hpi, infected cell supernatants were harvested and the
number of infectious virus particles determined by TCID50 assay in MDCK cells. Data
points represent the average and standard error of the mean. The horizontal dotted line is
the limit of detection.
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CHAPTER 3

Mutations in the membrane proximal region of the influenza A virus M2 protein
cytoplasmic tail have modest effects on virus replication

This chapter is reprinted here essentially as published.

Shaun M. Stewart and Andrew Pekosz.
J Virol doi:10.1128/JVI.05970-11 (2011).
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Abstract
Influenza A virus encodes M2, a proton channel that has been shown to be
important during virus entry and assembly. In order to systematically investigate the role
of the membrane proximal residues in the M2 cytoplasmic tail on virus replication, we
utilized scanning and directed alanine mutagenesis in combination with transcomplementation assays and recombinant viruses. The membrane proximal residues 4669 tolerated numerous mutations with little, if any, affect on virus replication suggesting
that protein structure, rather than individual amino acid identity in this region, may be
critical for M2 protein function.
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Introduction
Influenza A virus is a member of the Orthomyxovirdae family whose genome
consists of 8 negative-sense RNA segments which encode 10 or 11 proteins. The highly
conserved integral membrane protein M2 is encoded by segment 7 via a spliced mRNA,
consists of 97 amino acids, and forms disulfide-linked tetramers which have a pH-gated,
proton-selective ion channel activity. M2 is a type III integral membrane protein with an
extracellular amino-terminus and intracellular carboxy-terminus. M2 is required during
virus entry, where it translocates protons into the virion interior which allows for the
dissociation of viral ribonucleoprotein complexes (vRNPs) from the site of virus-cell
membrane fusion, thereby allowing vRNP transport to the nucleus (12, 18, 26). M2 is
also required during virus assembly where its cytoplasmic tail is required for proper
incorporation of vRNPs into budding virions (9, 19, 20). The M2 protein and a peptide
corresponding to an amphipathic helix in the membrane proximal cytoplasmic tail of the
protein, have been shown to induce membrane curvature and scission in unilamellar
vesicles and were suggested to be necessary for membrane scission and virion release
(31). However, virus-like particles (VLPs) (3, 4, 8, 15, 17, 39) and virions (6, 9, 13) can
be released in the absence of M2.
Various deletions and mutations in the M2 protein, and in particular the
cytoplasmic tail, attenuate influenza A virus replication significantly (9, 14, 19, 20) and
can be complemented with full length M2 expressed in trans (3, 9, 19, 20, 35). Residues
within the cytoplasmic tail form a canonical cholesterol-binding motif (CRAC) and have
been shown to mediate cholesterol binding in purified bacterially expressed protein and
during virus infection but not when expressed alone in mammalian cells (30, 33, 37).
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Mutation of residues within the CRAC motif caused no defect in virus replication in
tissue culture but a slight attenuation of virus in vivo (35). Although structural studies
have not been performed on the full-length M2 sequence, NMR studies on peptides
corresponding to the transmembrane domain and portions of the cytoplasmic tail reveal
that residues adjacent to the transmembrane domain form an amphipathic helix (25, 32,
34).
To systematically investigate the role of the membrane proximal residues (amino
acids 46-69) in the M2 cytoplasmic tail on virus replication, we substituted alanine
residues at a number of positions and assessed M2 protein function with a transcomplementation assay and reverse genetics. We show that the residues 46-69 tolerate
numerous mutations with little, if any, attenuation of virus replication in both
complementation assays and growth curves of recombinant viruses. Therefore, despite
being highly conserved and forming a stable structure, this region can tolerate a high
number of amino acid substitutions without significantly affecting influenza A virus
replication.

Materials and Methods
Plasmids. The plasmid pCAGGS (24) M2Ud expressing the M2 cDNA from
influenza A/Udorn/72 has been described previously (20). All M2 mutations were
introduced into the expression plasmid by overlap extension PCR (35). The pHH21 M
segment plasmid, which encodes the entire M segment used for generating recombinant
viruses (20), was mutated via QuikChange Site-Directed Mutagenesis (Stratagene) (35).
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All inserts in mutant plasmids were confirmed by sequencing. Primer sequences are
available upon request.
Cells. Madin-Darby canine kidney (MDCK) cells were cultured in Dulbecco’s
modified Eagle medium (DMEM, Sigma) supplemented with 10% fetal bovine serum
(FBS, Atlanta Biologicals), 100U/mL penicillin (Invitrogen), 100µg/mL streptomycin
(Invitrogen), 1mM sodium pyruvate (Sigma), and 2mM GlutaMAX (Invitrogen). Cells
were maintained at 37°C in a humidified 5% CO2 environment.
MDCK cells stably expressing wildtype M2Ud or M2WSN N31S have been
described previously (9, 35). The N31S mutation conveys amantadine sensitivity to the
M2 protein encoded by influenza A/WSN/33 (11, 36). The pBABE plasmid, which
expresses puromycin N-acetyltransferase (21) was used to generate MDCK cells stably
expressing mutant M2 proteins as described previously (35). Cells expressing M2
proteins were maintained with 5µM amantadine hydrochloride (Sigma) and 7.5µg/mL
puromycin dihydrochloride (Sigma).
Viruses. The wildtype viruses used in this study, rUd and rWSN (recombinant
versions of A/Udorn/72 [H3N2] and A/WSN/33 [H1N1]), as well as viruses encoding
functional deletions of the M2 open reading frame, have been described (20, 22, 36).
Recombinant viruses were generated using a 12-plasmid rescue system described
previously (19, 20, 22, 36). Recombinant viruses expressing mutant M2 proteins were
generated as described (9), by replacing the pHH21 M segment plasmid with one
encoding the indicated mutant M2 open reading frame. Viruses expressing mutant M2
proteins were plaque purified and grown in MDCK cells stably expressing M2WSN
N31S in order to alleviate any selective pressure on the virus to revert the M2 mutations.
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The entire coding region of the M segment of all rescued viruses was confirmed by
sequencing.
Virus infections. Multi-step virus growth curves were performed at a multiplicity
of infection (MOI) of 0.001 50% tissue culture infectious doses (TCID50) per cell. For
complementation assays, MDCK cells expressing mutant M2 proteins were infected with
recombinant viruses that do not encode the full-length M2 protein (M2Stop viruses) as
described (19). For recombinant viruses, mutant M2-expressing viruses were used to
infect MDCK cells. Cells were infected by twice washing confluent 12-well plates with
phosphate-buffered saline with calcium and magnesium (PBS+, Invitrogen) then
infecting with the indicated viruses in 250µL infectious media (DMEM supplemented
with 0.5% bovine serum albumin (BSA, Sigma), 100U/mL penicillin, 100µg/mL
streptomycin, 1mM sodium pyruvate, 2mM GlutaMAX, and 4µg/mL N-acetyl trypsin
(NAT, Sigma)) at room temperature with rocking for 1hr. Cells were then washed twice
with PBS+ and incubated with 500µL infectious media at 37°C. At indicated times,
media was removed, stored at -80°C, and replaced with fresh media. Infectious virus
titers were determined by TCID50 assay on MDCK cells expressing M2WSN N31S.
High MOI infections (MOI 0.5 or MOI 5) were performed using the protocol for
multi-step growth curves with the exception that both NAT and BSA were omitted during
all steps of infection. For protein expression studies, the media was removed at 16hpi and
cells were processed for Western blot analysis. For virion composition, the cell lysates
and supernatants were collected at 12hpi. Cell debris was removed from supernatants by
centrifugation at 1300g for 10 min at 4 °C. Virus particles were then concentrated
through a 35% sucrose cushion with centrifugation at 182,000g in a Sorvall TH-641 rotor
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for 1 h at 4 °C. Virus pellets were resuspended in 200 μL PBS, mixed 3:1 in 4xSDS–
PAGE sample buffer, and analyzed along with the cell lysates by Western blot analysis.
Plaque assay. Plaque assays were carried out by infecting confluent 6-well plates
of MDCK cells with indicated viruses serially diluted in infectious media. Cells were
washed twice with PBS+, infected with 250µL of virus dilutions for 1hr at room
temperature with rocking, the inoculums were aspirated, and cells were overlaid with
DMEM (Invitrogen) containing 1% agarose (Invitrogen), 0.5% BSA, 100U/mL
penicilillin, 100µg/mL streptomycin, 2mM GlutaMAX, and 4µg/mL NAT. After
overlays had solidified, the cells were incubated at 37°C for 3 days. Cells were then fixed
with 4% formaldehyde (Fisher Scientific) in PBS for 1hr at room temperature and stained
with a Naphthol Blue Black solution overnight. Individual plaque diameters were
measured from scanned images using ImageJ (NIH).
Microscopy. MDCK cells were grown to confluency on tissue culture treated
glass coverslips (Fisher Scientific) in 12-well plates and media was changed every 2
days. Four days after confluence, cells were infected with 500,000 TCID50 per well (MOI
~0.9) in 500µL of infectious media as per high MOI infections above and incubated at
37°C. At 15hpi, the cells were incubated on ice for 15min, washed twice with cold PBS+,
and blocked for 30min on ice in PBS with 0.5% BSA and 3% normal goat serum
(Sigma). Surface staining was performed for 1hr on ice in blocking solution containing
goat anti-H3 sera raised against A/Aichi/2/68 (1:500 dilution, V-314-591-157; National
Institute of Allergy and Infectious Diseases). Cells were then washed 3 times with cold
PBS+, fixed for 10min with 2% paraformaldehyde (Sigma) in PBS at room temperature
(RT), and incubated 1hr at RT with blocking solution containing donkey anti-goat IgG
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conjugated to AlexaFluor 555 (4µg/mL, Invitrogen). Cells were then washed twice with
PBS+ and mounted on slides using ProLong Gold anti-fade (Invitrogen).
Samples were imaged on a Nikon Eclipse 90i epifluorescence microscope.
Twenty non-overlapping images were taken of each sample using a 20x objective. For
each image, the total number of infected cells and cells expressing filaments were
counted and used to determine the percentage of infected cells expressing filaments.
TCID50 assay. MDCK cells expressing M2WSN N31S were plated in 96-well
plates. When confluent, cells were washed twice with PBS+, infected with 100µL of
virus serially diluted in infectious media, and incubated for 4 days at 37°C. Cells were
then fixed by adding 50µL of 4% formaldehyde in PBS, stained with a Naphthol Blue
Black solution, and scored for cytopathic effect. The 50% tissue culture infectious dose
(TCID50) was calculated by the method of Reed and Muench (27).
SDS-PAGE and Western blotting. Cells were lysed in 1% SDS (Fisher
Scientific) in PBS and mixed 1:1 in 2x SDS-PAGE sample buffer. Purified virus particles
were mixed 3:1 with 4x SDS-PAGE sample buffer. Sample buffer for samples analyzed
for total expression contained the reducing agent DTT while samples analyzed for
oligomerization did not. Proteins were resolved on 17.5% polyacrylamide gel with 4M
urea and transferred to polyvinylidene difluoride membranes (PVDF-FL, Millipore).
Wash buffer contained PBS with 0.3% Tween-20 (Sigma) and block buffer was wash
buffer with 5% dry milk added. Membranes were blocked for 30min at RT, incubated 2hr
RT with primary antibody, washed three times each for 5min, incubated 1hr RT with
secondary antibody, and washed four times each for 5min. Primary and secondary
antibodies were diluted in block buffer. The primary antibodies used were a mouse anti-
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M2 14C2 MAb (1:500 dilution) (40), goat anti-A/Udorn/72 (1:500 dilution) (41), and a
mouse anti-β-actin AC-15 MAb (1:10,000 dilution, Abcam). The AlexaFluor 647
conjugated secondary antibodies used were a goat anti-mouse immunoglobulin G (IgG), a
donkey anti-goat IgG, and a donkey anti-mouse IgG (all 1:500 dilution, Invitrogen). For
visualization, membranes were scanned using an FLA-5000 phosphorimager (FujiFilm).
Sequence alignments. All M2 protein sequences from H1N1 and H3N2 influenza
A virus strains (excluding pandemic 2009 H1N1 and laboratory strains) were obtained
from the NCBI Influenza Virus Sequence Database (1). Sequences were aligned using
ClustalW 2.0.10 (16). The percent of the sequences which encode the most conserved
residue at each amino acid was determined using WebLogo 3 (7).
Statistical analysis. Plaque diameters and percentage of infected cells
expressing filaments were compared using student t-tests. Growth curves were analyzed
using mixed ANOVAs and Bonferroni post-tests with time and virus titer as independent
variables in trans-complementation assays or in growth assays of recombinant viruses.
2Statistically significant differences of *p<0.05, **p<0.01, and ***p<0.001, are
indicated. All analyses were done with Prism 4.0 (GraphPad Software Inc.).

Results
Oligomerization and expression of mutant M2 proteins in stable cell lines.
The membrane proximal region of the M2 protein cytoplasmic tail consists of a region
that displays some sequence variability (amino acids 47-57) and a region that shows very
high conservation (amino acids 58-69) among seasonal influenza A virus strains (Fig
1A). In order to determine if residues 46-69 of the M2 protein cytoplasmic tail are
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required for protein function, two types of alanine-substitution mutations were generated
(Fig 1B). First, triple-scanning alanine mutations were generated across the region.
Second, an NMR structure (34) of the M2 protein was utilized to select amino acids
corresponding to two separate faces (M2UdCYTO and M2UdPORE) of the amphipathic
helix within the membrane proximal region cytoplasmic tail. Figure 1C shows the
residues 52, 53, 56, 57 and 60 of the helices which face the cytoplasm and were mutated
to alanines in the M2UdAlaCYTO mutant. Figure 1D shows the residues 51, 54, and 55
of the helix which face inward toward the amphipathic helixes of the other M2 peptides
and were mutated to alanines in the M2UdAlaPORE mutant. Alanine substitutions were
utilized in order to minimize structural perturbations on the amphipathic alpha helix
while still assessing the role of amino acid side chains on interactions with viral or
cellular factors.
Stably transfected MDCK cells were generated which express the mutant M2
proteins. All cell lines expressed M2 above the level required to complement M2deficient viruses (Fig 2A) (20). Additionally, the mutations do not alter the
oligomerization potential of M2 as determined by SDS-PAGE and Western blot analysis
under non-reducing conditions (Fig 2B).
M2 proteins are able to complement M2-null viruses. To study mutations
which may be deleterious to M2 function, a complementation assay was utilized (20).
Stably transfected MDCK cells were infected with two strains of M2-null virus, rUd
M2Stop (Fig 3A and B) or rWSN M2Stop (Fig 3C and D) (19). Neither rUd M2Stop nor
rWSN M2Stop are able to produce infectious virus on MDCK cells that do not express
M2 (Fig 3). The replication of rUd M2Stop in all mutant M2-expressing cell lines was
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not different from what was observed in wildtype M2-expressing cells (Fig 3A and B),
indicating that all of the mutated M2 proteins were capable of supporting rUdorn virus
replication.
rWSN M2Stop showed a minor, but statistically significant increase in virus
replication on cell lines expressing M2UdAla49-51 and M2UdAla67-69, while slightly
reduced replication was observed on cell lines expressing M2UdAla46-48 and
M2UdAlaPore (Fig 3 C and D). However, no differences at 24hpi or 48hpi were greater
than 1 log compared to the titer of rWSN M2Stop on cells expressing wildtype M2
protein. Despite these minor differences in replication, all cell lines expressing mutant
M2 proteins supported high levels of replication of rWSN M2Stop, consistent with the
data utilizing the rUd M2Stop virus (Fig 3A and B). Taken together, this suggests that the
region of M2 from residues 46-69 is highly amenable to mutation despite being highly
conserved.
Replication of recombinant influenza A viruses expressing M2 alanine
mutations. In order to further investigate the importance of M2 residues 46-69 on virus
replication, several recombinant viruses were generated in both the rUd and rWSN
background. Because expression of M2UdAla49-51 supported slightly greater replication
of rWSN M2Stop at two timepoints, a recombinant virus expressing this mutant were
generated. A virus expressing M2Ala67-69 were generated because its expression
supported higher levels of rWSN M2Stop at 48hpi (p<0.001). Lastly, because M2 has
been shown to interact with M1 (3, 19) and the cytosolically exposed face of the M2
amphipathic helix could mediate interactions with M1 or other proteins, viruses were also
generated which express M2AlaCYTO.
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Plaque assays were performed on MDCK cells to determine the plaque diameters
of each recombinant virus. Recombinant viruses expressing M2Ala49-51 or M2Ala67-69
formed smaller plaques in the rUd background but larger plaques in the rWSN
background compared to the respective wildtype viruses (Fig 4A and C). Expression of
M2AlaCYTO resulted in smaller plaques in rWSN but no difference in plaque diameter
in rUd as compared to wildtype viruses.
The decreased plaque diameter in mutant M2-expressing rUd viruses correlated
with the production of infectious virus at 24hpi in a low MOI growth curve (Fig 4B) but
by 48hpi there were no differences in infectious virus production between any of the
viruses. The ability of mutant M2-expressing rWSN viruses to form large or small
plaques did not fully correlate with their ability to replicate in a low MOI growth curve
(Fig 4D). rWSN expressing M2Ala49-51 formed larger plaques and had higher infectious
virus titers at 24hpi in the multi-step growth curve as compared to wildtype virus.
However, rWSN expressing M2Ala67-69 formed slightly larger plaques compared to
wildtype virus but resulted in similar levels of infectious virus at both 24hpi and 48hpi.
Additionally, expression of M2AlaCYTO in rWSN resulted in smaller plaques but more
infectious virus at 24hpi. Interestingly, despite some statistically significant changes at
24hpi, all mutant M2-expressing rUd and rWSN viruses formed similar amounts of
infectious virus at 48hpi compared to their respective wildtype recombinant viruses
suggesting that the membrane proximal region 46-69 of M2 can tolerate significant
mutations without eliminating the ability of influenza A virus to replicate.
Expression of M2UdAla67-69 is able to complement a recombinant virus
expressing M2Ala67-69. Because rUd M2Ala67-69 produced less infectious virus
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particles at 24hpi but rUd M2Stop replicated to similar levels on cells expressing
M2UdAla67-69, the growth of rUd M2Ala67-69 was compared to wildtype rUd in
MDCK, M2Ud-expressing, and M2UdAla67-69-expressing cells (Fig 5). In MDCK cells,
rUd M2Ala67-69 replicate to lower titers at 12hpi and 24hpi but had formed similar
amounts of infectious virus at 48hpi (Fig 5A). In M2Ud- or M2UdAla67-69-expressing
cells, both viruses produced similar amounts of infectious virus particles at all times
measured (Fig 5B). This indicates that expression of wildtype or or M2UdAla67-69 M2
is able to rescue any potential defect in production of infectious virus at early times post
infection. In order to determine if the level of M2 expressed by rUd M2Ala67-69 is
equivalent to that of wt virus, high MOI infections were performed on MDCK cells.
Expression of M2 was similar in cells infected by both viruses (Fig 5D), indicating that
the small defect in the growth of rUd M2Ala67-69 at 12hpi and 24hpi is not due to
decreased expression of M2 and suggests that perhaps a greater amount of M2 (either wt
or mutated protein) is needed for this virus to replicate efficiently.
M2 protein with alanine mutations at F47, F48, I51, Y52, and F55 is partially
able to complement M2-deficient viruses. Rossman et al. determined that alanine
substitution of residues F47, F48, I51, Y52, and F55 in the rUd M2 protein (M2AlaHelix,
Fig 1B & E) resulted in a recombinant virus severely debilitated in growth (30). Given
the limited effect of the mutations we introduced into the M2 protein on virus replication,
we sought to compare this mutant to our M2 mutants. Stably transfected MDCK cells
were generated which express the M2UdAlaHelix protein. The MDCK cell line
expressing M2UdAlaHelix expressed a similar level of M2 as compared to a cell line
expressing wildtype M2Ud (Fig 6A). Additionally, the M2UdAlaHelix mutant formed
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oligomers as determined by SDS-PAGE and Western blot analysis under non-reducing
conditions (Fig 6B).
In order to determine if constitutive expression of M2UdAlaHelix was able to
complement M2-null viruses, MDCK or M2-expressing MDCK cells were infected at a
low MOI and the amounts of infectious virus was determined at the indicated time post
infection. There was a reduction in the ability of M2UdAlaHelix to complement either
rUd M2Stop (Fig 6C) or rWSN M2Stop (Fig 6D). Both M2-null viruses grew to
infectious virus titers approximately 1-2 logs lower on M2UdAlaHelix expressing cells
than wild type M2-expressing cells at both 24hpi and 48hpi, which was a greater
attenuation than that seen on any other M2-expressing cell lines analyzed.
Recombinant influenza A virus expressing the M2UdAlaHelix protein is
attenuated at early time points but grows to similar peak titers. Because the
attenuation of rUd M2Stop on cells expressing M2UdAlaHelix was less than what was
expected based on data with a recombinant virus expressing this mutant M2 protein (30),
we generated a recombinant Ud virus expressing the M2UdAlaHelix protein to further
characterize this mutation. Plaque assays of this recombinant, rUd M2AlaHelix, on
MDCK cells showed significantly smaller plaques when compared to wildtype rUd (Fig
7A). Low MOI growth curves revealed a decrease in production of infectious virus
particles at 24hpi, but by 48hpi, rUd M2AlaHelix had produced as much infectious virus
as recombinant wildtype rUd. Sequence analysis of the rUd M2AlaHelix virus produced
at this timepoint demonstrated that no changes in the M-segment sequence had
accumulated, indicating that a revertant virus had not emerged (data not shown). The
ability of rUd M2AlaHelix to form filaments in virus-infected cells was not significantly
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different when compared to rUd (Fig 7C). The expression levels of HA, NP, and M1
proteins were similar in cells infected with either wildtype rUd or rUd M2AlaHelix (Fig
7D). Western blot analysis of pelleted rUd M2AlaHelix virus particles showed no major
defective in the secretion of virus particles as well as no defect in the incorporation of
HA, NP, or M1 (Fig 7D). The modest level of attenuation and lack of significant changes
in structural protein packaging seen with rUd M2AlaHelix was not consistent with what
was observed in previous reports (30). However, this data is consistent with the data on
other M2 mutations generated in this region of the protein (Figures 3 and 4), which
indicate a limited role for membrane proximal amino acids 46-69 of M2 in supporting
influenza A virus infectious virus production.

Discussion
The influenza A virus M2 protein plays a crucial role during several steps of the
viral life cycle. During virus entry, the ion channel activity of M2 mediates the release of
vRNPs into the cytoplasm after HA-induced fusion of the viral and cellular membranes.
Additionally, the M2 cytoplasmic tail is critical for proper incorporation of vRNPs into
budding particles. The exact mechanism of the incorporation might occur through
binding of NP and/or M1. Indeed there is support for the latter in that M1 and M2 have
been shown to interact with each other (3, 19). Two separate M1 binding sites have been
identified within M2, one within the amino acids 70-77 (3, 19) and another within
residues 45-69 (19).
The membrane proximal region consisting of amino acids 46-69 is believed to
mediate association of M2 with sites of virus budding. This region consists of a
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palmitoylation site, a cholesterol binding motif, and an amphipathic helix that can insert
into the lipid bilayer (23, 25, 32, 34, 38). Although palmitoylation was expendable for
growth in vitro, mutation of the palmitoylated cysteine at residue 50 led to a reduction in
pathogenesis in mice (10) and was required for the partial raft partitioning of full-length
M2 in giant plasma membrane vesicles (37). Mutation of the critical residues within the
cholesterol binding motif caused no effect on in vitro growth but a small reduction of
morbidity and mortality associated with infection in mice (35). This study sought to
investigate which residues in the membrane proximal region 46-69 of the M2 protein
cytoplasmic tail were required for the function of M2 during virus replication.
Two distinct recombinant strains of influenza A virus, A/Udorn/72 and
A/WSN/33, were utilized. rUd is an H3N2 strain that forms both spherical and
filamentous virus particles while rWSN is an H1N1 mouse-adapted strain that almost
exclusively forms spherical virus particles (2, 28, 29). While some M2 mutations have
been shown to be deleterious to virus replication in both virus strains, others have been
shown to more deleterious in rUd (9, 19). During infection with rUd, less M2 protein is
expressed in cells and, therefore, less M2 protein is incorporated into virus particles
compared to infection with rWSN (10, 35).
Triple-scanning alanines were made across the residues 46-69 to systematically
test the necessity of these highly conserved residues for the formation of infectious virus
particles. Furthermore, two separate faces of the amphipathic helix found in the M2
protein cytoplasmic tail were also separately mutated to alanines, M2UdAlaCYTO and
M2UdAlaPORE. All of these M2 mutants were able to complement two strains of
influenza A viruses lacking functional M2, rUd M2Stop and rWSN M2Stop (Fig 3).
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Moreover, recombinant viruses expressing several of these M2 mutants were generated
and grew to similar peak titers at 48hpi (Fig 4). Taken together, these data show that the
membrane proximal residues 46-69 of the M2 protein can tolerate significant mutations
without eliminating the ability of virus to replicate. While none of these mutated M2
proteins had any major effect on the replication of rUdorn viruses, it is interesting to note
that two mutations, Ala49-51 and Ala67-69, caused a slight but significant increase in
replication in rWSN. This demonstrates the importance of assessing M2 mutations in
different influenza A virus strains. The variable results of these mutations may map to
other viral proteins, as was demonstrated for virus budding (5) and for infectious virus
production (9, 19).
Analysis of a recent NMR structure revealed that some of the nonpolar residues
within the amphipathic helix from one monomer interact with residues in the loop
between the transmembrane domain and the amphipathic helix of another monomer (34).
L46 was shown to interact with F54 and F48 was shown to interact with both F55 and
L59. . Interestingly, one of the large hydrophobic residues in each of those pairs is
mutated in the M2AlaPORE mutant, F54 and F55. Despite disruption of these
interactions, these mutations did not abrogate the functions of the M2 protein during virus
replication (Fig 3B and D). However, it is conceivable that mutating these residues from
phenylalanines to alanines was insufficient to fully disrupt these hydrophobic
interactions. Additionally, the NMR structure revealed that the charged residues K49,
R53, H57, K60, and R61 project outward and could interact with the negatively charged
phospholipids. . The M2AlaCYTO mutant has several of these amino acids altered from
charged residues to alanines (R53A, H57A, and K60A), yet this mutant retains its ability
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to complement M2-null viruses (Fig 3B and D) and recombinant viruses expressing it
show no defect in replication (Fig 4B and D).
These data contrast somewhat with a study by Rossman et al., that demonstrated a
critical role for the membrane proximal, cytoplasmic region of the M2 protein in virus
budding and membrane scission (30). In that study, while single point mutations at
positions 47, 48, 51, 52 and 55 did not affect virus assembly and budding, combining all
those mutations led to a greater than 5 log reduction in infectious virus production and a
decrease in NP incorporated relative to the other viral proteins (30). These mutations
abrogated the ability of a peptide corresponding to this region of the M2 protein to induce
membrane scission in unilamellar vesicles and also reduced the ability of full length M2
to induce VLPs (31). The significance of this is not completely clear since VLPs are
formed in the absence of M2 expression (3, 4, 8, 15, 17, 39) and viruses encoding either a
mutation in the M2 5’ splice site or a nonfunctional M2 both express undetectable levels
of M2 protein yet produce virus particles with decreased infectivity (6, 9, 13), thus
demonstrating that M2 is not absolutely necessary for membrane scission of influenza A
virus particles. We also generated an M2 protein with alanine substitutions at positions
47, 48, 51, 52, and 55 and demonstrated a 1-2 log decrease in infectious virus production
from cells expressing M2UdAlaHelix compared to cells expressing wildtype M2 in a
trans-complementation assay. The defect in infectious virus production was more
pronounced in infections with rUd M2Stop as compared to rWSN M2Stop. A
recombinant rUd virus encoding the M2AlaHelix was able to form filaments and had no
defect in NP incorporation (Fig 7C and D) whereas the same virus reported by Rossman
et al was unable to form filaments and had a defect in NP incorporation (30). The rUd
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M2AlaHelix that we generated also showed reduced replication kinetics which were not
as large (1-2 log reduction at 24 hpi and identical titers at 48 hpi, Fig 7B) as that reported
by Rossman et al, (~3 logs at 24hpi and ~5 logs at 48hpi) when compared to wildtype
rUd (30). Although both growth curves were performed at the same 0.001 MOI, the
amount of infectious virus was measured differently, plaque assay versus TCID50 assay.
However, titration of stocks of rUd M2AlaHelix by the two assays showed comparable
titers (data not shown) indicating the method of detecting infectious virus was not
responsible for the discrepancy in attenuation.
This study sought to investigate whether the membrane proximal residues 46-69
of the M2 protein cytoplasmic tail were required for the function of M2 during virus
replication. Given the fact that numerous mutations were made in this region of the M2
protein and in both complementation assays and recombinant viruses these mutations
caused little, if any, attenuation in virus replication, we conclude that the region is
tolerable of numerous amino acid substitutions before protein function is compromised.
Protein structure, rather than individual amino acid identity, may be critical for the
function of this region of the M2 protein. It will be important to utilize a structural
biology approach in order to gain further knowledge about the role of this region on M2
function.
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Figure Legends

Figure 1. Sequence and structural location of M2 cytoplasmic tail amino acids. A)
Conservation of residues 46-69 of the M2 protein among H1N1 (virus sequences prior to
2009) and H3N2 influenza A virus strains. B) Sequence of residues 46-69 of wildtype
M2 protein and alanine substitutions. The amphipathic helix is highlighted in yellow (34).
C-E) Structures of M2 proteins (residues 22-62) with mutated amino acids in green.
Residue 22 appears at the top of the structures on the left. The structures on the right are
rotated 90⁰ as indicated in order to view the cytosolic face of the M2 tetramer. C)
M2UdCYTO - Y52, R53, E56, H57, and K60; D) M2UdPORE - I51, F54, and F55; E)
M2UdHelix - F47, F48, I51, Y52, and F55. Structures were generated using PyMol from
PDB code 2LOJ.

Figure 2. Expression and oligomerization of mutant M2 proteins. A) MDCK cells
stably expressing the indicated M2 proteins were analyzed by Western blotting in order
to determine (A) the overall expression under reducing conditions and (B) the presence of
disulfide linked oligomers under non-reducing conditions. Monomeric M2 and the cell
protein loading control, β-actin, are indicated in (A) and monomers, dimers, and
tetramers of M2 are indicated in (B).

Figure 3. Complementation of M2-deficient viruses by expression of mutant M2
proteins. MDCK cells stably expressing the indicated M2 protein were infected at an
MOI of 0.001 with a recombinant influenza A virus that does not encode the full-length
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M2 protein. The amount of infectious virus at each time point was determined by TCID50
assay on cells expressing wildtype M2. Complementation of rUd M2Stop virus (A and B)
or rWSN M2Stop virus (C and D) infectivity on cells expressing the indicated M2
protein. The mean and standard error of the mean of triplicate samples are graphed from a
representative experiment. The limit of detection is marked by a horizontal dotted line.

Figure 4. Plaque size and replication kinetics of recombinant viruses expressing
mutated M2 proteins. (A and C) Plaque diameter of MDCK cells infected with the
indicated recombinant viruses at 3 days post infection (dpi). The cells were fixed and
stained with a Naphthol Blue Black solution and individual plaque diameters were
measured from scanned images using ImageJ. A representative example is shown from
triplicate experiments. Student t-tests were performed to determine significant differences
as compared to wild type virus. (B and C) MDCK cells were infected at an MOI of 0.001
with the indicated recombinant virus. At the indicated hours post infection (hpi), cell
supernatants were collected and the numbers of infectious virus particles were
determined by TCID50 assay on M2-expressing cells. The mean and standard error of the
mean of triplicate samples are graphed from a representative experiment. The limit of
detection is marked by a horizontal dotted line.

Figure 5. Complementation of a recombinant virus expressing M2Ala67-79. (A-C)
MDCK (A), M2Ud-expressing (B), and M2UdAla67-69-expressing cells (C) were
infected at an MOI of 0.001 with the indicated recombinant virus. At the indicated hpi,
cell supernatants were collected and the numbers of infectious virus particles were
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determined by TCID50 assay on cells expressing wildtype M2. The mean and the standard
error of the mean of triplicate samples are graphed from a representative experiment. The
limit of detection is marked by a horizontal dotted line. (D) MDCK cells were infected at
an MOI of 0.5 with the indicated recombinant virus. At 16hpi, expression of M2 and the
cell protein loading control, β-actin, were compared in cell lysates by Western blot.

Figure 6. Expression and function of M2UdAlaHelix protein. Western blot analysis of
MDCK cells stably expressing either wildtype M2Ud or M2UdAlaHelix. (A) The total
expression of M2 protein under reducing conditions and (B) the presence of disulfide
linked oligomers under non-reducing conditions. Monomeric M2 and the cell protein
loading control, β-actin, are indicated in (A) and monomers, dimers, and tetramers of M2
are indicated in (B). (C and D) MDCK cells stably expressing the indicated M2 protein
were infected with the indicated recombinant virus that does not encode the full-length
M2 protein at an MOI of 0.001. The amount of infectious virus at each time point was
determined by TCID50 assay on cells expressing wildtype M2. The mean and standard
error of the mean of triplicate samples are graphed from a representative experiment. The
limit of detection is marked by a horizontal dotted line.

Figure 7. Characterization of a recombinant virus expressing M2AlaHelix. (A)
Plaque diameter of MDCK cells infected with recombinant viruses expressing either
wildtype M2 or M2AlaHelix at 3dpi. The individual and average diameters of plaques
were determined. A representative example is shown from triplicate experiments. (B)
MDCK cells were infected at an MOI of 0.001 with the indicated viruses. At the
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indicated hpi, cell supernatants were collected and the numbers of infectious virus
particles were determined by TCID50 assay on M2-expressing cells. The mean and
standard error of the mean of triplicate samples are graphed from a representative
experiment. The limit of detection is marked by a horizontal dotted line. (C) MDCK
cells, infected with 500,000 TCID50 of indicated virus, were stained for
immunofluorescence at 15hpi and visualized by microscopy. The percent and average
percent of infected cells showing filaments were determined from 20 non-overlapping
images taken with an epifluorescence microscope. One representative experiment is
shown. (D) MDCK cells were infected at an MOI of 5 with the indicated viruses. At
12hpi, supernatants were collected and virus particles were concentrated by
ultracentrifugation through 35% sucrose in PBS, resuspended in PBS, and equal volumes
were analyzed along with the cell lysates by Western blotting under reducing conditions.
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CHAPTER 4

The influenza C virus CM2 protein can alter intracellular pH and its
transmembrane domain can substitute for that of the influenza A virus M2 protein
and support infectious virus production

This chapter is reprinted here essentially as published.

Shaun M. Stewart and Andrew Pekosz.
J Virol doi:10.1128/JVI.05681-11 (2011).
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Abstract
The influenza C virus CM2 protein and a chimeric influenza A virus M2 protein
(MCM) containing the CM2 transmembrane domain were assessed for their ability to
functionally replace the M2 protein. While all three proteins could alter cytosolic pH to
varying degrees when expressed from cDNA, only M2 and MCM could at least partially
restore infectious virus production to M2-deficient influenza A viruses. The data suggest
that while the CM2 ion channel activity is similar to that of M2, sequences in the
extracellular and/or cytoplasmic domains play important roles in infectious virus
production.
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The influenza A virus M2 protein is a homotetrameric, type III integral membrane
protein that functions at several stages of the viral life cycle (24). The proton-selective
ion channel activity of M2 (4, 18) mediates the release of viral ribonucleoprotein
complexes (vRNPs) from matrix (M1) and viral membranes, allowing migration of
vRNPs to the nucleus (9, 15, 23) and also raises the pH of the exocytic pathway, thereby
preventing premature low pH-induced conformational changes in hemagglutinin (HA) (5,
26). The cytoplasmic tail of M2 is also required for efficient genome packaging into
budding virus particles (8, 16, 17). M2 has also been proposed to be mediate membrane
scission, however, in the absence of M2, infected and transfected cells release virus
particles and virus like particles, respectively (2, 3, 8, 14, 25).
The influenza C virus CM2 protein is an integral membrane protein generated
after proteolytic cleavage of an internal signal peptide of the p42 protein (10, 13, 22).
CM2 forms disulfide-linked homotetramers (12, 21) and has been shown to conduct Clions (11) or perhaps protons (19). CM2 has been shown to be involved in the release of
vRNPs during virus uncoating and in packaging of vRNPs during virus assembly (7).
CM2 is also able to raise the pH of the exocytic pathway; however, the role of this
activity during influenza C virus replication is currently unclear (1). This study sought to
investigate whether full length CM2 or a chimeric M2 protein containing the CM2
transmembrane domain could functionally substitute for the influenza A virus M2
protein.
CM2, normally generated from proteolytic cleavage from p42, can be expressed
efficiently from cDNA using the vaccinia virus-bacteriophage T7 polymerase expression
system (21) but expression levels are low from plasmids that rely on host cell
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transcription machinery. Efficient plasmid-based expression of CM2 was achieved by
deleting the p42 internal signal peptide from the expression plasmid (20), most likely
because of the elimination of a mRNA splice donor site present in the RNA
corresponding to the signal peptide. The glycosylation site was eliminated by mutating
Thr at residue 37 to Ala and epitope tags for the antibodies 3F10 (anti-hemagglutinin
epitope) and 14C2 (anti-M2 epitope) were added at the carboxy-terminus in order to
facilitate detection of the protein (Fig 1A). In order to determine if the ion channel
activity of CM2 can substitute for that of M2, a construct was generated with the
extracellular and cytplasmic tail of M2 and the TM of CM2 (MCM), Fig 1A.
Because some reports show that M2 and CM2 have differential ion channel
activity yet both are able to raise the pH of the secretory pathway (1, 5, 6, 11, 19), the ion
channel activity of the two proteins was compared in an assay that measures pHdependent changes in eYFP fluorescence (8). Whereas low-pH treatment of 293T cells
co-transfected with eYFP and an empty vector yielded no change in mean fluorescence
intensity (MFI) over time, low-pH treatment of cells co-transfected with eYFP and M2
from A/Udorn/72 (M2Ud) resulted in ~40% decrease in MFI (Fig 1B-C). Low-pH
treatment of cells co-transfected with eYFP and CM2 only resulted in ~25% decrease in
MFI (Fig 1D), indicating the CM2 protein was able to modulate the cytoplasmic pH of
transfected cells but not to the same extent as the M2 protein. The MCM protein induced
a reduction in eYFP fluorescence which resembled that of CM2 (Fig 1E), suggesting that
substitution of the CM2 TM for that of M2 conferred ion channel activity that resembled
that of CM2. The level of expression of M2, CM2 and MCM in transfected 293T cells
was comparable (Fig 1C- E), indicating that the decreased pH changes induced by CM2
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and MCM compared to M2 were not attributable to differential protein levels but most
likely reflected altered ion channel activity.
In order to determine if CM2 and MCM were able to complement a M2-null
influenza A virus, clonal MDCK cell lines stably-expressing the proteins were generated.
Total expression of CM2 and MCM are shown relative to cell lines expressing M2Ud or
M2 from A/WSN/33 with a mutation conveying amantadine resistance (M2WSN N31S)
(Fig 2A) (27, 28). The expression level of MCM was similar to that of M2, while the
CM2 protein expression level was only 2% of the levels of M2. However, even trace
amounts of M2 protein can functionally complement an M2-null influenza A virus (17)
so the levels of CM2 expression are expected to be sufficient for the complementation
assay. MCM was able to form disulfide-linked oligomers, similar to the M2 and CM2
proteins (Fig 2B). In order to determine if constitutive expression of CM2 or MCM
prevented replication of influenza A virus, recombinant A/Udorn/72 (H3N2, rUd) and
recombinant A/WSN/33 (H1N1, rWSN) were titered on the cell lines (Fig 2C). Both rUd
and rWSN had similar titers on all cell lines tested, suggesting that expression of CM2 or
MCM does not inhibit influenza A virus infection. To assess the ability of CM2 and
MCM to substitute for M2, the recombinant M2-null viruses rUd M2Stop & rWSN
M2Stop (8, 27) were titered on the cell lines (Fig 2C). Both rUd M2Stop and rWSN
M2Stop showed decreased titers on CM2-expressing cells compared to M2-expressing
cells, indicating CM2 cannot functionally replace M2. When comparing MCM to M2expressing cells, rUd M2Stop had similar titers while rWSN M2Stop showed a decrease
in titer, demonstrating that the MCM protein can complement rUd M2Stop but not rWSN
M2Stop, which suggests that the CM2 ion channel activity can functionally substitute for
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that of M2 in some influenza A virus strains. However, given the low level of CM2
expression, it remains to be determined if overexpression of the CM2 protein to levels
much higher than those needed for M2 complementation, can partially complement an
M2-null influenza virus.
The ability of MCM to substitute for M2 was also tested in multi-step growth
curves (Fig 2D-E). Neither rUd M2Stop nor rWSN M2Stop were able to grow in CM2expressing cells despite the fact that the level of CM2 expression was higher than that
needed to complement these viruses with M2 protein (8, 16, 17). MCM-expressing cells
did support growth of both viruses, but the growth of rWSN M2Stop was more attenuated
than rUd M2Stop. Since CM2 expression could not complement while MCM expression
could partially complement two different M2-null viruses, we conclude that that the ion
channel activity of CM2 can replace that of M2; however, the ectodomain and/or the
cytoplasmic tail of M2 are required during influenza A virus replication.
M2 mutations that cause strain specific defects in growth of either rUd or rWSN
have previously mapped to the M1 protein (2, 8, 16). The ability of MCM expression to
complement rUd M-WSN M2Stop (expressing 7 segments from Ud, M1 from WSN, and
no M2) growth was comparable to its ability to complement rUd M2Stop (Fig 2D&F).
Likewise, the ability of MCM expression to complement rWSN M-Ud M2Stop
(expressing 7 segments from WSN, M1 from Ud, and no M2) growth was comparable to
its ability to complement rWSN M2Stop (Fig 2E&G). Together, these data indicate that
the decreased ability of MCM to complement rWSN M2Stop maps to viral sequences
outside of the M1 protein.
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The inability of CM2 to complement M2-null viruses could be due to a defect in
particle budding. Virus particles from high MOI infections were concentrated by
ultracentrifugation through 35% sucrose and analyzed by Western blot and TCID50 assay
(Fig 3). As previously published, rUd M2Stop virus particles from MDCK cells are
released but are defective in the incorporation of full length NP (NPa) and have lower
infectious virus titers relative to total HA (Fig 3A-C) (8). rWSN M2Stop virus particles
grown on MDCK cells also have decreased titer relative to total HA but increased release
and cleavage of HA (Fig 3D-E). Both M2-null viruses grown on CM2-expressing cells
showed similar phenotypes compared to those grown on MDCK cells (Fig 3). However,
rUd M2Stop virus particles grown on MCM-expressing cells incorporated MCM and did
not show the decreased incorporation of NPa observed in virus particles isolated from
MDCK and CM2-expressing cells (Fig 3A-C). rWSN M2Stop virus particles grown on
MCM-expressing cells also had similar structural protein incorporation compared to
particles from M2-expressing cells. The ratio of titer to HA (a measure of the infectivity
of the particles) of viruses grown on MCM-expressing cells was intermediate of that from
those grown on MDCK or CM2-expressing cells versus M2-expressing cells (Fig 3C&E).
Taken together this data demonstrates that expression of MCM, but not CM2, is able to
complement the defect of NPa incorporation present in viruses grown on MDCK cells but
that the particles from MCM-expressing cells still have a defect in infectivity which is
more apparent in rWSN M2Stop versus rUd M2Stop.
Negative stain electron microscopy was performed on the purified rUd M2Stop
virus particles in order to assess any morphological differences in virus particles grown
on the various cell lines. rUd M2Stop particles grown on MDCK or CM2-expressing
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cells had a smaller average diameter and higher particle/TCID50 ratios than those grown
on M2-expressing cells (Fig 4). Virus particles isolated from MCM-expressing cells were
of similar size to those grown on M2-expressing cells, but had slightly higher
particle/TCID50 ratios (Fig 4F). All cell lines produced comparable numbers of particles
(Fig. 4F). These data indicate that the infectivity of the virus particles correlated with the
size of the particles, and that MCM, but not CM2, could partially complement the rUd
M2stop virus.
These studies suggest that influenza A virus produced in the absence of M2 or in
the presence of CM2 has a defect in the incorporation of NPa (and most likely, vRNA),
smaller particles, an increased ratio of total to infectious particles, and absence of growth
in multi-step growth curves. The level of CM2 expression was higher than the level of
M2 expression needed for complementation, however we cannot rule out the fact that
higher levels of CM2 expression might lead to some degree of complementation or that
the addition of C-terminal epitope tags may be interfering with CM2 protein function.
Virus particles produced in the presence of MCM incorporate a normal level of NPa and
are of normal size but have a slightly reduced infectivity. We hypothesize that the defect
in infectivity of virus particles grown on MCM-expressing cells is due to the differential
ion channel activity of the MCM protein versus the M2 protein. The ion channel activity
(Fig 1) shows that MCM does not lower the pH of the cytoplasm as efficiently as M2,
most likely leading to a decreased ability to release vRNPs during virus entry.
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Figure Legends

Figure 1. Schematic and ion channel activity of M2, CM2, and MCM. A) Schematic
of the ectodomain (Ecto), transmembrane domain (TM), and cytoplasmic tail (Cyto) of
wildtype M2, CM2, and MCM. Amino acid numbers are indicated. Sequences recognized
by the HA (black box) and M2 (hatched box) antibodies are also shown. B-E) The ability
of M2, CM2, and MCM to conduct ions was indirectly measured using the pH-sensitive
fluorescent protein eYFP. 293T cells were transiently transfected with plasmids encoding
eYFP and either an empty pCAGGS expression plasmid or a pCAGGS plasmid
expressing the indicated protein. The next day, cells were detached and resuspended in
media at either pH 7.4 or pH 5.8 and analyzed by flow cytometry. The mean fluorescence
intensity (MFI) of 10,000 cells was determined every 15 sec. The change in MFI versus
time is plotted from a representative experiment performed at least twice. Solid lines
represent curve fits to one phase exponential decay models and dotted lines represent no
change in MFI. The expression levels of M2, CM2, and MCM in eYFP positive cells was
determined by flow cytometry using the 14C2 antibody and a goat anti-mouse antibody
conjugated to AlexaFluor 647. The MFI and standard deviation are presented in each
panel.

Figure 2. Expression, oligomerization, and complementation ability of M2, CM2,
and MCM. A and B) MDCK cells or MDCK cells stably expressing the indicated
proteins were analyzed by Western blotting in order to determine (A) the total expression
under reducing conditions and (B) the presence of disulfide linked oligomers under non-
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reducing conditions. Antibodies were α-M2 MAb 14C2 (1:500), α-β-actin MAb
(1:10,000, Abcam AC-15), and goat α-mouse IgG conjugated to AlexaFluor 647 (1:500,
Invitrogen). Monomeric proteins and the cell protein loading control, β-actin, are
indicated in (A) and monomers, dimers, and tetramers are indicated in (B). Relative
expression levels of M2, CM2, and MCM, normalized to M2WSN N31S, are listed
below the corresponding lane. C) Titers of the indicated recombinant virus were
determined by TCID50 assay on MDCK cells or MDCK cells stably expressing the
indicated protein. The mean and the standard error of the mean are graphed from two
independent experiments. D-G) MDCK cells or MDCK cells stably expressing the
indicated protein were infected at an MOI of 0.001 with the indicated recombinant
influenza A viruses. The amount of infectious virus at each time point was determined by
TCID50 assay on cells expressing wildtype M2. The mean and the standard error of the
mean are graphed. The limit of detection is marked by a horizontal dotted line. Infectious
virus production from 24-72 hr was analyzed using mixed ANOVAs with time and virus
as independent variables using Prism 4.0. Statistical differences between viruses grown
on M2-expressing cells and MCM-expressing cells are indicated, ***p<0.001.

Figure 3. Analysis of structural proteins incorporated into M2-null viruses. rUd
M2Stop (A-C) or rWSN M2Stop (D-E) virus particles grown on the indicated cell lines
were concentrated by ultracentrifugation through 35% sucrose in PBS, resuspended in
PBS, and analyzed by Western blotting under reducing conditions and by TCID50 assay
on wildtype M2-expressing cells expressing. A and D) Incorporation of various structural
proteins into M2-null viruses are indicated from images scanned using an FLA-5000. B)
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The relative amount of NPa incorporated into rUd M2Stop virus particles was quantified
from Western blots and is indicated as a ratio to total HA0. C and E) The relative titer of
each sample is indicated as a ratio of the titer versus total HA0, as determined by Western
blot analysis. The mean and the standard error of the mean are graphed from at least two
independent experiments and the Western blots represent one of the quantified replicates.

Figure 4. Morphology of M2-null virus grown on cell lines expressing M2, CM2, or
MCM. rUd M2Stop virus particles grown on MDCK cells or MDCK cells stably
expressing the indicated protein were concentrated through PBS containing 35% sucrose
as in Fig 3. Samples were mixed 1:1 with a 1:500 dilution of 100nm Nanosphere beads
(Thermo Scientific). 2uL was allowed to dry onto a 400 mesh carbon and parlodion
coated copper grid, negatively stained with filtered 1% aqueous phosphotungstic acid pH
7.0, and blot dried with filter paper. Samples were viewed on a Hitachi H-7600 TEM
operating at 80 kV and digitally captured with an AMT CCD at 1k x 1k resolution. A-E)
Representative electron micrographs of virus particles grown on various cell lines,
including the average and standard deviation of the particle diameter as measured on the
longest axis (n≥17). Scale bar represents 100nm. F) The total particles (determined from
the known concentration of Nanosphere beads (29)) and the ratio of total particles to
TCID50 titer are graphed from three separate experiments.
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Conclusions
The highly conserved type III integral membrane protein M2 consists of 97 amino
acids and forms disulfide-linked tetramers which have a pH-gated, proton-selective ion
channel activity (10, 32, 35). M2 is required during virus entry, where it translocates
protons into the virion interior which allows for the dissociation of viral
ribonucleoprotein complexes (vRNPs) from the site of virus-cell membrane fusion,
thereby allowing nuclear transport of the vRNPs (18, 28, 34). M2 is also required during
virus assembly where it is important for proper incorporation of vRNPs into budding
virus particles (7, 16, 21, 29, 30).
M2 contains several domains, an N-terminal ectodomain, a transmembrane
domain, and a C-terminal cytoplasmic tail. The cytoplasmic tail can be divided into two
regions based upon deletion mutants and function mapping, the membrane proximal
region, residues 46-69, and the membrane distal region, residues 70-97 (Fig 1). The
membrane distal region has been studied extensively and is required for proper budding
and vRNP incorporation (7, 16, 21, 29, 30). However, much less is known about the role
of the membrane proximal region in virus replication. The NMR structure of the
transmembrane domain and most of membrane proximal region (residues 22-62) was
recently determined by two groups (38, 40). These structures confirm that residues 48-58
form an amphipathic helix. This amphipathic helix also seems to stabilize the tetrameric
structure of M2, particularly at low pH when the ion channel is open.
The primary aim of this thesis was to determine the role of the membrane
proximal region of the M2 cytoplasmic tail in M2 incorporation and virus replication.
Several potential methods of M2 incorporation were previously suggested that
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encompassed the membrane proximal region including cholesterol binding (39) and
interactions with M1 (7, 29). I attempted unsuccessfully to co-immunoprecipate
cholesterol and full length M2 transiently expressed from cDNA. Later, others showed
that cholesterol could only be pulled down by anti-M2 immunoprecipitations from
cellular extracts in context of virus infection, ie the co-expression of other viral proteins
(36). Since this cholesterol co-immunoprecipitation requires other viral proteins, some of
which, HA and NA, are located at sites enriched in cholesterol, and M2, NA, and HA all
get incorporated into virus particles, it is probable that this cholesterol coimmunoprecipitation may be mediated by indirect interactions with other viral proteins.
Indeed, I found that the cholesterol binding motif in M2 is not required for M2
incorporation or virus replication in tissue culture in either a trans-complementation
system or in recombinant viruses expressing mutant M2 proteins (43). Alteration of the
cholesterol binding motif did modestly attenuated the morbidity and mortality induced by
recombinant virus in mice, suggesting that this region may be a virulence factor (43).
I also studied the other hypothesis, that interactions between M1 and M2 drive the
incorporation of M2. Two M1 binding sites within the M2 cytoplasmic tail have been
previously mapped, one in the membrane proximal region and another in the membrane
distal region (29, 30). Deletion or mutation of amino acids in the membrane distal region
lead to decreased vRNA incorporation but do not affect M1 or M2 incorporation (7, 16,
29, 30). I used scanning and directed alanine mutagenesis in trans-complementation
assays and recombinant viruses to determine if the membrane proximal region of M2 was
important for M2 incorporation and virus replication. I determined that this region can
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sustain numerous linear and structure based mutations with little, if any, effect on virus
replication and M2 incorporation (42).
My last aim started as an attempt to use chimeric proteins between influenza A
virus M2 and an M2 homolog in influenza C virus, CM2, to determine which regions of
M2 were most important for M2 function, incorporation, and virus replication.
Unfortunately, several of the chimeric constructs were not expressed at the cell surface
correctly, possibly due to differences in the normal way in which M2 and CM2 undergo
membrane insertion during translation. This issue prevented a complete analysis of which
domains of M2 were necessary and sufficient for M2 incorporation and virus replication.
However, one construct, an M2 chimera expressing the CM2 transmembrane domain
(MCM), was expressed properly and utilized, along with M2 and CM2, in order to
compare the ion channel function and the ability of the transmembrane of CM2 to replace
that of M2 during virus infection. I determined that CM2 and MCM both had similar
abilities to alter the cytosolic pH when expressed at the cell surface, but that only MCM
was able to rescue the infectivity of an M2-null virus (41). This further confirmed that
residues in the ectodomain and cytoplasmic tail of M2 are important in the assembly of
infectious influenza A virus. This also demonstrated for the first time that the ion channel
activity of CM2, although different from M2, is sufficient to induce the release of
influenza A vRNPs during virus entry.

Current Budding Model
Combining the data presented in this thesis along with other recently published
data, I propose the following model for virus budding (Fig 2). After viral transcription
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and translation, the major structural proteins and vRNPs traffic to the plasma membrane.
The glycoproteins HA and NA traffic with detergent-resistant membrane microdomains
to the cell surface (11, 26, 47). At early times after infection, M2 has a more random
distribution across the cell surface than HA and NA, does not co-localize in one
dimension with HA in immunogold labeled thin-section electron micrographs (TEM),
and is susceptible to cold detergent extraction (26, 39, 47). However, at later times after
infection, M2 is seen to co-localize two-dimensionally with HA in immunogold labeled
electron micrographs of planar sheets of plasma membrane (7). This suggests that as viral
proteins begin to accumulate at the cell surface late during infection, M2 and HA begin to
localize to similar regions despite remaining in unique microdomains of the plasma
membrane (Fig 2A).
Some evidence suggests that Rab11, a small GTP-binding protein involved in
trafficking of non-raft proteins to the apical recycling endosome (ARE) en route to the
plasma membrane, is required for M2 but not HA trafficking to the plasma membrane
(11, 37). M2 has been shown previously to be important for vRNP incorporation (7, 16,
29, 30) and my studies show that in the absence of M2, budded virus particles are indeed
smaller, probably reflecting a defect in vRNP incorporation (41). I propose that M2 and
vRNPs directly interact while in transport to or after M2 arrives at the plasma membrane.
Like M2 trafficking, correct trafficking of vRNPs also require Rab11 (2, 12, 31). This
suggests, but does not definitely prove, that M2 and vRNPs interact at the ARE during
transport and arrive at the plasma membrane together. Either way, interaction and
localization together at the plasma membrane (Fig 2B) may occur before, after, or at the
same time as M1 begins to bind to the membrane (Fig 2C) and oligomerize (Fig 2D).
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M1 has the inherent ability to bind membranes, oligomerize, and induce particle
formation in the absence of the other viral proteins (15, 17, 22, 46). However, studies also
show that M1 interacts with the HA and NA cytoplasmic tails and that this interaction
directs M1 to detergent-resistant membrane microdomains, where HA and NA are
enriched (1). Therefore, this proposed budding model emphasizes that these interactions
between M1 and the glycoproteins may assist M1 oligomerization and increase viral
budding (Fig 2D).
TEM and cryo-electron microscopy (cryo-EM) reveal that in filamentous
influenza virus particles, the vRNPs are located at the distal end of the budding particles
(6, 33). Given that M2 is important in vRNP incorporation and that vRNPs, when
incorporated, are located at the distal end of particles, I propose that M2 interacting with
vRNPs at the plasma membrane becomes the seed with which M1 interacts to drive
budding (Fig 2E-F). However, in the absence of M2, virus particles are still produced
demonstrating M2 is not required for budding (9, 16, 20, 41), and in the presence of M2,
empty particles are formed in addition to infectious particles (33). Together these data
suggest that either some particles are seeded by M2 which do not have bound vRNPs or,
even when M2 is present, M1 induces some particles to form without the M2/vRNP seed.
These particles, without vRNPs would be non-infectious and be in agreement with why
few particles are detected that do not contain a partial complement of eight vRNPs (33).
M1 forms a helical lattice around the vRNPs just inside the viral membrane and the
cytoplasmic tails of HA, NA, and M2 protrude through holes in this lattice given the
glycoproteins regular order on the surface of the virus (6).
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This model does not address how particles undergo membrane scission and are
released. There is little data on cellular factors that might be involved in this step. M2 and
a peptide corresponding to the M2 amphipathic helix, have been shown to induce
membrane curvature and scission in unilamellar vesicles and were suggested to mediate
membrane scission and virion release (37). However, virus-like particles (VLPs) (7, 8,
15, 24, 25, 44) and virions (9, 16, 20) can be released in the absence of M2. Perhaps, like
respiratory syncytial virus (RSV), influenza membrane scission is mediated by cellular
factors which bind Rab11 (5, 45).

Future Directions
These studies provide evidence that the cholesterol binding motif is not important
during replication in tissue culture but partially modulates pathogenesis in mice.
Determining why viruses with an alteration of this motif are attenuated in mice will be
important. Perhaps cholesterol binding by M2 can act to sequester cholesterol thereby
modulating normal cellular functions. However, the fact that the type of cholesterol
binding motif found in M2 is generally not one identified as cholesterol sequestering
argues against this hypothesis. Nonetheless, it should be evaluated by comparing the
effect of cholesterol metabolism in cells expressing either wildtype M2 or the cholesterol
binding motif mutant. It would also be interesting to study the effect of cholesterol levels
on virus replication; however, cholesterol depletion has been shown to have multiple
non-M2 associated affects on influenza virus replication including disruption of HA and
NA containing membrane microdomains, increased particle budding, and decreased
particle stability (3).
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Given that cholesterol can only be immunoprecipitated in the presence of the
expression of the other viral proteins (36), it is also possible that the role of this region as
a virulence factor is not related to cholesterol binding. Indeed the first 60 amino acids of
M2, which include the cholesterol binding motif, are able to bind Beclin-1 and inhibit the
maturation of autophagosomes (14). Inhibition of this pathway by HIV blocks autophagy
mediated virion degradation and could also do so for influenza A virus (23). As such, it
should be determined if mutation of the residues in the cholesterol binding motif prevents
the inhibition of autophagosome maturation.
Although the alanine mutagenesis of the membrane proximal region showed, little
or no effect on replication of virus, it will be interesting to see if these mutants, like the
virus expressing the cholesterol binding mutant, are attenuated in mice. If some are
attenuated and others are not, it would serve to further define the region of M2 that may
be a virulence factor in mice. Along with morbidity and mortality, the levels of viral
replication and virus-induced cytokine production should be determined since both are
associated with severe influenza pathogenesis.
Experiments also showed that a recombinant rUd (H3N2) influenza virus (rUd
M2AlaHelix) expressing five alanine substitutions in the membrane proximal region of
M2, at residues F47, F48, I51, Y52, and F55, grew to lower infectious titers at 24hpi but
produced similar levels of infectious virus at 48hpi compared to wildtype (42).
Furthermore, there was no apparent defect in incorporation of HA, M1, or NP in this
virus. These findings differed from a similar recombinant virus previously published that
produced 4-5 logs less infectious virus at all times hpi tested and had decreased
incorporation of NP (36). In order to confirm the results of the recombinant virus, I also
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used a trans-complementation system to test the requirement of these five amino acids on
virus replication. Although complementation of M2-null viruses with the expression of
this mutant did decrease production of infectious virus at all times hpi, it was only
decreased by ~1-2 logs (42). These findings together contradict the suggestion that these
five amino acids are required in tissue culture as reported (36). It will be important to test,
side-by-side, the rUd M2AlaHelix generated previously with the one described here in
order to reconcile their phenotypic differences.
All mutations to date in the M2 amphipathic helix have focused on maintaining
the structure of the helix while altering the identities of individual amino acids or altering
charge faces. It would be beneficial in future studies to either make mutations that are
predicted to interrupt the helical structure, perhaps by inserting prolines and/or glycines,
or to insert a sequence between the transmembrane and amphipathic helix that is unable
to form a helix.
Another finding in this dissertation that should be followed up relates to the ion
channel activity of CM2. It has previously been suggested that CM2 is not required to
pump ions inside the uncoating virion in influenza C virus, like it is in influenza A virus,
because low pH did not separate M1 from vRNPs (48). However, two lines of evidence
suggest that a low pH burst may in fact also be required for influenza C virus. First, CM2
has ion channel activity and can result in lowered pH (4, 19, 41). Second, similar to M2,
CM2 is required for nuclear migration of vRNPs during virus uncoating (13). In light of
the data presented in this thesis, I hypothesize that for influenza C virus low pH is
required to separate M1/vRNPs from membranes but not each other. Alternatively, since
CM2 may be able pump chloride ions (19), the separation of M1/vRNPs might occur at
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different relative salt concentrations compared to influenza A virus M1/vRNPs. Future
work should reevaluate the ability of low pH to separate influenza C virus M1/vRNPs
from membranes and M1 from vRNPs at various pH levels and salt concentrations.
Related to the ability of CM2 to lower cytosolic pH, it was interesting that
expression of MCM but not CM2 was able to complement M2-null viruses in a strain
specific manner. MCM complemented rUd strains better than rWSN (H1N1) M2-null
strains and this phenotype did not map to M1 as have so many other strain specific effects
of M2 have in the past (7, 16, 29). One hypothesis about why MCM is able to
complement rUd strains better than rWSN strains of influenza is that the M2-mediated
release of vRNPs during entry requires different pH in the two strains. This is in
agreement with the findings that M2 incorporation is much lower in wildtype rUd
compared to rWSN and that MCM has decreased abilities to alter pH compared to M2
(41). It will be important to test this hypothesis by purifying M1/vRNP complexes from
either cells or virus particles and determine the pH that is required for separation of M1
and vRNPs from both strains of viruses, as has been done previously to compare other
influenza reassortants (27).

Implications
The M2 protein is required for virus entry and assembly. First generation
adamantane pharmaceuticals, amantadine and rimantadine, have been available for a
number of years and work by blocking the ion channel activity of M2. However,
resistance to these drugs easily arises and most circulating H3N2 strains are already
resistant to both drugs. Mutations that convey resistance to adamantanes so readily
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appear in the population probably due to several reasons. One, M2 is required for virus
replication. Two, very high levels of drug are required in vitro in order to completely
block ion channel activity and are potentially not achievable in vivo. Lastly, different
strains may require more or less M2 ion channel activity for replication. Together this
suggests that M2 is a great drug target but that better drugs must be discovered. Many
resources are being invested in optimizing adamantanes, but little to date has provided
promise. This thesis increases our knowledge of M2 and suggests that new drugs should
target functions of M2 in the ectodomain and cytoplasmic tails of the protein.
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Figure Legends

Figure 1. Schematic of functional domains of M2. M2 contains three domains, an Nterminal ectodomain, a transmembrane domain, and a C-terminal cytoplasmic tail. The
cytoplasmic tail can be artificially divided into two parts based upon function. The
membrane distal region includes residues 70-97 and has been shown to be important for
virus budding and vRNP incorporation. The membrane proximal region also contains
several important functions and was further studied in this thesis. The schematic shows
an image of the crystal structure of residues 22-62 (PDB 2LOJ) generated with PyMol
along with lines representing the ectodomain and remainder of the cytoplasmic tail
(residues 63-97). Extra is the extracellular space, PM is the plasma membrane, and Cyto
is the cytosol.

Figure 2. Model of infectious influenza A virus assembly. A) After viral transcription
and translation, the major structural proteins and viral ribonucleoprotein complexes
(vRNP) accumulate at the plasma membrane. The glycoproteins HA and NA traffic to
similar membrane microdomains (purple), which resemble lipid rafts. M2 has a more
random distribution across the cell surface and does not accumulate in HA and NAcontaining microdomains (grey). B) M2, which is known to interact with vRNPs, may do
so at this time. C) M1 has the inherent ability to bind the inner leaflet of the plasma
membrane. D) M1, either already bound to the membrane or from a cytoplasmic pool,
binds the cytoplasmic tails of HA and NA and undergoes oligomerization. The order of
B-D may be different or the steps may occur simultaneously. E) M1 interacts with M2
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and initiates membrane curvature and viral budding around the vRNPs. In the absence of
M2, M1 still induces budding, but vRNP incorporation is impaired. F) After budding is
initiated, M2 and the vRNPs are located at the distal end of filamentous particles. M1-M1
interactions direct the continued growth of virus particles by the aggregation and
incorporation of HA and NA-containing microdomains. At some point, unknown cellular
factors are probably recruited to the bud and induce membrane scission, releasing the
virus particle. M1-M1 structure around the distal vRNPs has been omitted for clarity.
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Figure 1. Schematic of functional domains of M2.
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